1
|
Oh KK, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Jeong MK, Min BH, Hyun JY, Eom JA, Park HJ, Yoon SJ, Choi MR, Kim DJ, Suk KT. The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis. Artif Cells Nanomed Biotechnol 2023; 51:217-232. [PMID: 37129458 DOI: 10.1080/21691401.2023.2203734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
We comprised metabolites of gut microbiota (GM; endogenous species) and dietary plant-derived natural flavonoids (DPDNFs; exogenous species) were known as potent effectors against non-alcoholic fatty liver disease (NAFLD) via network pharmacology (NP). The crucial targets against NAFLD were identified via GM and DPDNFs. The protein interaction (PPI), bubble chart and networks of GM or natural products- metabolites-targets-key signalling (GNMTK) pathway were described via R Package. Furthermore, the molecular docking test (MDT) to verify the affinity was performed between metabolite(s) and target(s) on a key signalling pathway. On the networks of GNMTK, Enterococcus sp. 45, Escherichia sp.12, Escherichia sp.33 and Bacterium MRG-PMF-1 as key microbiota; flavonoid-rich products as key natural resources; luteolin and myricetin as key metabolites (or dietary flavonoids); AKT Serine/Threonine Kinase 1 (AKT1), CF Transmembrane conductance Regulator (CFTR) and PhosphoInositide-3-Kinase, Regulatory subunit 1 (PIK3R1) as key targets are promising components to treat NAFLD, by suppressing cyclic Adenosine MonoPhosphate (cAMP) signalling pathway. This study shows that components (microbiota, metabolites, targets and a key signalling pathway) and DPDNFs can exert combinatorial pharmacological effects against NAFLD. Overall, the integrated pharmacological approach sheds light on the relationships between GM and DPDNFs.
Collapse
Affiliation(s)
- Ki-Kwang Oh
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Haripriya Gupta
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Raja Ganesan
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Satya Priya Sharma
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Sung-Min Won
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Jin-Ju Jeong
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Su-Been Lee
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Min-Gi Cha
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Goo-Hyun Kwon
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Min-Kyo Jeong
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Byeong-Hyun Min
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Ji-Ye Hyun
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Jung-A Eom
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Hee-Jin Park
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Sang-Jun Yoon
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Mi-Ran Choi
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Dong Joon Kim
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Ki-Tae Suk
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| |
Collapse
|
2
|
Oh KK, Choi I, Gupta H, Raja G, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Jeong MK, Min BH, Hyun JY, Eom JA, Park HJ, Yoon SJ, Choi MR, Kim DJ, Suk KT. New insight into gut microbiota-derived metabolites to enhance liver regeneration via network pharmacology study. Artif Cells Nanomed Biotechnol 2023; 51:1-12. [PMID: 36562095 DOI: 10.1080/21691401.2022.2155661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
We intended to identify favourable metabolite(s) and pharmacological mechanism(s) of gut microbiota (GM) for liver regeneration (LR) through network pharmacology. We utilized the gutMGene database to obtain metabolites of GM, and targets associated with metabolites as well as LR-related targets were identified using public databases. Furthermore, we performed a molecular docking assay on the active metabolite(s) and target(s) to verify the network pharmacological concept. We mined a total of 208 metabolites in the gutMGene database and selected 668 targets from the SEA (1,256 targets) and STP (947 targets) databases. Finally, 13 targets were identified between 61 targets and the gutMGene database (243 targets). Protein-protein interaction network analysis showed that AKT1 is a hub target correlated with 12 additional targets. In this study, we describe the potential microbe from the microbiota (E. coli), chemokine signalling pathway, AKT1 and myricetin that accelerate LR, providing scientific evidence for further clinical trials.
Collapse
Affiliation(s)
- Ki-Kwang Oh
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ickwon Choi
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Haripriya Gupta
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ganesan Raja
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Satya Priya Sharma
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Sung-Min Won
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Jin-Ju Jeong
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Su-Been Lee
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Min-Gi Cha
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Goo-Hyun Kwon
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Min-Kyo Jeong
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Byeong-Hyun Min
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ji-Ye Hyun
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Jung-A Eom
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Hee-Jin Park
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Sang-Jun Yoon
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Mi-Ran Choi
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Dong Joon Kim
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ki-Tae Suk
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| |
Collapse
|
3
|
Lee O, Choi MR, Cottone G, Patel P, Clare SE, Khan SA. Abstract P3-13-03: Heterozygous BRCA1 mutation influences alternative splicing in human benign mammary organoids. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p3-13-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Women carrying a germline BRCA1 mutation, have 60% risk of developing breast cancer during their lifetime and frequently develop triple-negative, basal-like, aggressive breast tumors. Humans produce around 150,000 different proteins from their 25,000-30,000 genes. This is accomplished by alternative splicing (AS). We hypothesized that AS in BRCA1 mutation carriers is different from those women with wild type BRCA1, therefore, we examined AS, expression of genes encoding splicing factors, and enrichment of binding motifs for RNA-binding proteins in BRCA1 carriers (BRCA1mut/+) and controls (BRCA1 normal). Methods: Prophylactic mastectomy (BRCA1mut/+) and reduction mammoplasty (BRCA1 normal) specimens were collected at Prentice Women’s Hospital of Northwestern Medicine under approval by Northwestern’s Institutional Review Board (NU15B07). We isolated organoids from these tissues, and cryopreserved them for future use. We selected organoids of premenopausal women, age-matched (28-46) without oral contraceptive usage within 3 years: BRCA1mut/+ (n=12) and BRCA1 normal (n=4). Organoids were maintained in complete MammoCult medium in ultra-low attachment plates at 37 °C, 5% CO2 for 72 hrs, and harvested for RNA extraction (NucleoSpin RNA Plus, TaKaRa). 100 ng of total RNA (RIN 7+) were used for RNA sequencing assay with the KAPA mRNA Hyper Prep Kit (Roche Corporate) and NovaSeq 6000 for 100b paired-end sequencing (Illumina, Inc). The preprocessed reads were aligned to the human genome (hg38) using STAR. Differential expression analysis (DESeq2, nominal p-value < 0.05) and pathway analysis (GSEA, size ≥30, NES >2, FDR q-value <0.05, and enriched genes ≥ 5) were performed to compare BRCA1mut/+ with BRCA1 normal. We used rMATS- turbo v4.1.0 to perform multivariate analysis of transcript splicing and chose an FDR < 0. 05, to identify significant differential alternative splicing events. To determine which RNA binding proteins and splicing factors were employed in BRCA1mut/+ tissue, we examined the cis-regulatory motifs adjacent to splice sites using rMAPs. Results: BRCA1mut/+ organoids displayed 155 upregulated genes compared to BRCA1 normal organoids (P <0.05). Among top 20 enriched pathways, we identified that expression of mRNA spliceosome (POLR2L, U2AF2, NUP188, SNRPF, CSTF3, HNRNPM, SRSF2), and, in addition, cell cycle, oxidative phosphorylation, HIV infection, and protein metabolism genes were significantly upregulated in BRCA1mut/+ organoids. We identified significant differential AS events (FDR <0.05) between BRCA1mut/+ and BRCA1 normal organoids: 2159 genes (skipped exon), 433 genes (mutually exclusive exon), 325 genes (retained intron), 304 genes (alternative 3’ splice sites), 168 genes (alternative 5’ splice sites). RNA splicing analysis indicated that highly expressed genes (SRSF2, ALG3, AP1B1 and PMF1) in BRCA1mut/+ organoids were also alternatively spliced. In addition, many other serine/arginine-rich splicing factors (SRSF) themselves (SRSF1, 2, 3, 5, 6, 7) were alternatively spliced (skipped exon events). An examination of binding motifs of RNA-binding proteins with significantly increased expression in BRCA1 carriers revealed multiple significantly enhanced and silenced regions flanking exons involved in AS. Conclusions: Our data suggest that AS of BRCA1mut/+ mammary tissue significantly differ from BRCA1 normal tissue, and may alter RNA spliceosome activity, and consequently play a role in malignant transformation and warrant further study.
Citation Format: Oukseub Lee, Mi-Ran Choi, Gannon Cottone, Priyam Patel, Susan E Clare, Seema A. Khan. Heterozygous BRCA1 mutation influences alternative splicing in human benign mammary organoids [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-13-03.
Collapse
|
4
|
Davaadelger B, Choi MR, Singhal H, Clare SE, Khan SA, Kim JJ. BRCA1 mutation influences progesterone response in human benign mammary organoids. Breast Cancer Res 2019; 21:124. [PMID: 31771627 PMCID: PMC6878650 DOI: 10.1186/s13058-019-1214-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Accepted: 10/15/2019] [Indexed: 01/12/2023] Open
Abstract
Background Women, who carry a germline BRCA1 gene mutation, have a markedly increased risk of developing breast cancer during their lifetime. While BRCA1 carriers frequently develop triple-negative, basal-like, aggressive breast tumors, hormone signaling is important in the genesis of BRCA1 mutant breast cancers. We investigated the hormone response in BRCA1-mutated benign breast tissue using an in vitro organoid system. Methods Scaffold-free, multicellular human breast organoids generated from benign breast tissues from non-carrier or BRCA1 mutation carriers were treated in vitro with a stepwise menstrual cycle hormone regimen of estradiol (E2) and progesterone (P4) over the course of 28 days. Results Breast organoids exhibited characteristics of the native breast tissue, including expression of hormone receptors, collagen production, and markers of luminal and basal epithelium, and stromal fibroblasts. RNA sequencing analysis revealed distinct gene expression in response to hormone treatment in the non-carrier and BRCA1-mutated organoids. The selective progesterone receptor modulator, telapristone acetate (TPA), was used to identify specifically PR regulated genes. Specifically, extracellular matrix organization genes were regulated by E2+P4+TPA in the BRCA1-mutated organoids but not in the non-carrier organoids. In contrast, in the non-carrier organoids, known PR target genes such as the cell cycle genes were inhibited by TPA. Conclusions These data show that BRCA1 mutation influences hormone response and in particular PR activity which differs from that of non-carrier organoids. Our organoid model system revealed important insights into the role of PR in BRCA1-mutated benign breast cells and the critical paracrine actions that modify hormone receptor (HR)-negative cells. Further analysis of the molecular mechanism of BRCA1 and PR crosstalk is warranted using this model system.
Collapse
Affiliation(s)
- Batzaya Davaadelger
- Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 4-117, Chicago, IL, 60611, USA
| | - Mi-Ran Choi
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Hari Singhal
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Susan E Clare
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Seema A Khan
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - J Julie Kim
- Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 4-117, Chicago, IL, 60611, USA.
| |
Collapse
|
5
|
Choi MR, Yadav S, Shidfar A, Khan SA, Clare SE. Abstract P3-09-02: CRISPR-Cas9 mediated BRCA1 mutation in primary cells: Mutation efficiency and effects. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Germline mutations in Breast Cancer Associated (BRCA) 1 or 2 genes confer an increased risk of the development of breast and ovarian cancer. Germline mutation is followed by somatic loss of heterozygosity (LOH) resulting in biallelic inactivation. BRCA1 is involved in multiple homeostatic functions including control of chromatin organization, gene transcription, protein stability and cell division. Recent studies have demonstrated heterogeneity in LOH within and between premalignant and malignant breast tissues of BRCA1 mutation carriers. We hypothesize that LOH does not have a unitary effect on phenotype but differs by the function that is abrogated.
Methods: To test our hypothesis, we adopted CRISPR-Cas9 gene editing technology. The guide RNAs for targeting the exon sequence in the RING finger, nuclear export signal (NES), nuclear localization signal (NLS) and BRCA1 C Terminus (BRCT) domain/motif of BRCA1 were designed and synthesized. MCF10A cells were transfected with a complex of guide RNA and Cas9 protein (RNP) to cause in/del mutation. The mutation was analyzed by both T7E1 assay, and an innovative and more precise method developed in our lab that utilizes linked nucleic acids (LNA) and qPCR. Proliferation and apoptosis assays were performed using the transfected cells. Organoids prepared from BRCA1 mutation carriers also were transfected with RNPs and the mutation burden determined.
Results: Since single cell clones of the transfected MCF10A cells could not be selected and expanded, a pool of transfected cells was used for the analyses. T7E1 assay and qPCR analysis using LNAs demonstrated the presence of the mutations. A standard curve was created to enable the calculation of the mutation burden. IncuCyte analysis revealed increased proliferation and apoptosis, induced by irradiation, in cells with the mutation in Exon 10, where the extent of increase varied from 11% to 48% depending on the degree of mutation. In contrast, cells with the mutation in Exon 5 displayed diminished proliferation with no change in apoptosis. That mutations in exon10 and 5 have distinct biological effects when compared to the mutations in other exons is intriguing, and modification of binding proteins will be investigated. Organoids generated from BRCA1 mutation carriers (primary and nonmalignant cells) were able to be successfully transfected using the NEON electroporation system. Mutations were introduced by the CRISPR-Cas9 system and their extent quantified by our LNA-mediated qPCR method.
Conclusions: CRISPR-Cas9-mediated gene editing of BRCA1 in MCF10A resulted in a change in the proliferation rate and the extent of apoptosis that is dependent on the location of the de novo mutation within the gene. The development of a novel method, LNA-mediated qPCR, provides quantitative information regarding the mutations that may be used to correlate mutation burden with biological functional change. Successful establishment of this BRCA1 tumorigenesis model has provided us with a method to test other putative tumor suppressors.
Citation Format: Choi MR, Yadav S, Shidfar A, Khan SA, Clare SE. CRISPR-Cas9 mediated BRCA1 mutation in primary cells: Mutation efficiency and effects [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-09-02.
Collapse
Affiliation(s)
- MR Choi
- Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - S Yadav
- Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - A Shidfar
- Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - SA Khan
- Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - SE Clare
- Feinberg School of Medicine, Northwestern University, Chicago, IL
| |
Collapse
|
6
|
Min MH, Park JH, Choi MR, Hur JH, Ahn BN, Kim DD. Formulation of a film-coated dutasteride tablet bioequivalent to a soft gelatin capsule (Avodart ®): Effect of γ-cyclodextrin and solubilizers. Asian J Pharm Sci 2018; 14:313-320. [PMID: 32104461 PMCID: PMC7032202 DOI: 10.1016/j.ajps.2018.08.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 08/26/2018] [Accepted: 08/30/2018] [Indexed: 01/24/2023] Open
Abstract
The aim of this study was to optimize a tablet formulation of dutasteride that is bioequivalent to a commercially available soft gelatin capsule (Avodart®). The effect of cyclodextrin on enhancing the aqueous solubility of dutasteride was investigated, after which the formulation was further optimized with solubilizing polymer and surfactant. Among the cyclodextrins tested, the highest solubility was observed when dutasteride was complexed with γ-cyclodextrin. Moreover, the addition of polyvinylpyrrolidone and Gelucire/TPGS further enhanced the solubility of dutasteride. Differential scanning calorimetry (DSC) and powder X-ray diffraction (pXRD) studies demonstrated that dutasteride existed in the amorphous form in the complex. Optimized dutasteride complexes were selected after a pharmacokinetic study in rats, and film-coated tablets were prepared by the direct compression method. In vitro dissolution profiles for the tablets of dutasteride complexes were similar to those of the reference. Moreover, pharmacokinetic parameters including the Cmax and AUC values after oral administration in beagle dogs were not significantly different from those of the reference with a relative bioavailability of 92.4%. These results suggest the feasibility of developing a tablet formulation of dutasteride using cyclodextrin complex in addition to a solubilizing polymer and surfactant.
Collapse
Affiliation(s)
- Mi-Hong Min
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.,Central Research Institute, Whanin Pharmaceutical Company, 4F, GBSA, 107 Gwanggyo-ro, Yeongtong-gu, Suwon 16229, Republic of Korea
| | - Jin-Hyong Park
- Central Research Institute, Whanin Pharmaceutical Company, 4F, GBSA, 107 Gwanggyo-ro, Yeongtong-gu, Suwon 16229, Republic of Korea
| | - Mi-Ran Choi
- Central Research Institute, Whanin Pharmaceutical Company, 4F, GBSA, 107 Gwanggyo-ro, Yeongtong-gu, Suwon 16229, Republic of Korea
| | - Jong-Hyun Hur
- Central Research Institute, Whanin Pharmaceutical Company, 4F, GBSA, 107 Gwanggyo-ro, Yeongtong-gu, Suwon 16229, Republic of Korea
| | - Byung-Nak Ahn
- Central Research Institute, Whanin Pharmaceutical Company, 4F, GBSA, 107 Gwanggyo-ro, Yeongtong-gu, Suwon 16229, Republic of Korea
| | - Dae-Duk Kim
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea
| |
Collapse
|
7
|
Chun JW, Choi J, Cho H, Choi MR, Ahn KJ, Choi JS, Kim DJ. Role of Frontostriatal Connectivity in Adolescents With Excessive Smartphone Use. Front Psychiatry 2018; 9:437. [PMID: 30258373 PMCID: PMC6143708 DOI: 10.3389/fpsyt.2018.00437] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 08/23/2018] [Indexed: 01/08/2023] Open
Abstract
As smartphone use has grown rapidly over recent decade, it has been a growing interest in the potential negative impact of excessive smartphone use. In this study, we aim to identify altered brain connectivity associated with excessive smartphone use, and to investigate correlations between withdrawal symptoms, cortisol concentrations, and frontostriatal connectivity. We focused on investigating functional connectivity in frontostriatal regions, including the orbitofrontal cortex (OFC), midcingulate cortex (MCC), and nucleus accumbens (NAcc), which is related to reward processing and cognitive control. We analyzed data from 38 adolescents with excessive smartphone use (SP) and 42 healthy controls (HC). In the SP group compared with HC, we observed lower functional connectivity between the right OFC and NAcc, and between the left OFC and MCC. Moreover, functional connectivity between the MCC and NAcc was greater in SP compared with HC. Subsequently, we examined the relationship between Internet use withdrawal symptoms, cortisol concentrations, and functional connectivity between the OFC and NAcc in SP and HC. We observed that more severe withdrawal symptoms were associated with higher cortisol concentrations in adolescents with excessive smartphone use. The most interesting finding was that we observed a negative correlation between OFC connectivity with the NAcc and both withdrawal symptoms and cortisol concentrations. The functional connectivity between the OFC and NAcc, and between the OFC and MCC are related to cognitive control of emotional stimuli including reward. The current study suggests that adolescents with SP had reduced functional connectivity in these regions related to cognitive control. Furthermore, Internet use withdrawal symptoms appear to elicit cortisol secretion, and this psychophysiological change may affect frontostriatal connectivity. Our findings provide important clues to understanding the effects of excessive use of smartphones on brain functional connectivity in adolescence.
Collapse
Affiliation(s)
- Ji-Won Chun
- Department of Psychiatry, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
| | - Jihye Choi
- Department of Psychiatry, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
| | - Hyun Cho
- Department of Psychiatry, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea.,Department of Psychology, Korea University, Seoul, South Korea
| | - Mi-Ran Choi
- Department of Psychiatry, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
| | - Kook-Jin Ahn
- Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
| | - Jung-Seok Choi
- Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, South Korea
| | - Dai-Jin Kim
- Department of Psychiatry, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
| |
Collapse
|
8
|
Wang J, Shidfar A, Ivancic D, Ranjan M, Liu L, Choi MR, Parimi V, Gursel DB, Sullivan ME, Najor MS, Abukhdeir AM, Scholtens D, Khan SA. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. Int J Cancer 2017; 140:2484-2497. [PMID: 28263391 DOI: 10.1002/ijc.30680] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 12/21/2016] [Accepted: 02/14/2017] [Indexed: 12/31/2022]
Abstract
Risk biomarkers for estrogen receptor (ER)-negative breast cancer have clear value for breast cancer prevention. We previously reported a set of lipid metabolism (LiMe) genes with high expression in the contralateral unaffected breasts (CUBs) of ER-negative cancer cases. We now further examine LiMe gene expression in both tumor and CUB, and investigate the role of Pre-B-cell leukemia homeobox-1 (PBX1) as a candidate common transcription factor for LiMe gene expression. mRNA was extracted from laser-capture microdissected epithelium from tumor and CUB of 84 subjects (28 ER-positive cases, 28 ER-negative cases, 28 healthy controls). Gene expression was quantitated by qRT-PCR. Logistic regression models were generated to predict ER status of the contralateral cancer. Protein expression of HMGCS2 and PBX1 was measured using immunohistochemistry. The effect of PBX1 on LiMe gene expression was examined by overexpressing PBX1 in MCF10A cells with or without ER, and by suppressing PBX1 in MDA-MB-453 cells. The expression of DHRS2, HMGCS2, UGT2B7, UGT2B11, ALOX15B, HPGD, UGT2B28 and GLYATL1 was significantly higher in ER-negative versus ER-positive CUBs, and predicted ER status of the tumor in test and validation sets. In contrast, LiMe gene expression was significantly lower in ER-negative than ER-positive tumors. PBX1 overexpression in MCF10A cells up-regulated most LiMe genes, but not in MCF10A cells overexpressing ER. Suppressing PBX1 in MDA-MB-453 cells resulted in decrease of LiMe gene expression. Four binding sites of PBX1 and cofactor were identified in three lipid metabolism genes using ChIP-qPCR. These data suggest a novel role for PBX1 in the regulation of lipid metabolism genes in benign breast, which may contribute to ER-negative tumorigenesis.
Collapse
Affiliation(s)
- Jun Wang
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Ali Shidfar
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - David Ivancic
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Manish Ranjan
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Liannian Liu
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Mi-Ran Choi
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Vamsi Parimi
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Demirkan B Gursel
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Megan E Sullivan
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Matthew S Najor
- Department of Medicine, Rush University Medical Center, Chicago, IL
| | - Abde M Abukhdeir
- Department of Medicine, Rush University Medical Center, Chicago, IL
- Department of Pharmacology, Rush University Medical Center, Chicago, IL
| | - Denise Scholtens
- Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Seema A Khan
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
| |
Collapse
|
9
|
Hwang JH, Yoon JH, Bae YM, Choi MR, Lee SY, Park KH. Effect of the precutting process on sanitizing treatments for reducing pathogens in vegetables. Food Sci Biotechnol 2017; 26:531-536. [PMID: 30263575 DOI: 10.1007/s10068-017-0073-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 01/05/2017] [Accepted: 01/05/2017] [Indexed: 10/19/2022] Open
Abstract
The effectiveness of sanitizing treatments was investigated on reducing pathogens inoculated in whole or cut fresh vegetables, including Brussels sprouts, carrots, cherry tomatoes, paprika, and lettuce. These products were inoculated with Escherichia coli O157:H7, Salmonella enterica serovar Typhimurium, and Listeria monocytogenes and then treated with chlorine and alcohol sanitizers, followed by the subsequent washing procedure in sterile distilled water at 25°C for 5min. Alcohol sanitizer was the most effective in inhibiting E. coli O157:H7, S. Typhimurium, and L. monocytogenes on cut Brussels sprouts, showing bacterial reductions of 4.16, 3.60, and 3.26 log CFU/g, respectively. Interestingly, the effects of sanitizing treatments were significantly lower for fresh cut produce than those for whole products (p<0.05), indicating that the effectiveness of sanitizers would be different, depending on fresh produce and the pre-cut process. Therefore, further information should be obtained to develop an effective sanitizing treatment for fresh produce.
Collapse
Affiliation(s)
- Jin-Ha Hwang
- 1Department of Food and Nutrition, Chung-Ang University, Anseong, Gyeonggi, 17546 Korea
| | - Jae-Hyun Yoon
- 1Department of Food and Nutrition, Chung-Ang University, Anseong, Gyeonggi, 17546 Korea
| | - Young-Min Bae
- 1Department of Food and Nutrition, Chung-Ang University, Anseong, Gyeonggi, 17546 Korea
| | - Mi-Ran Choi
- 1Department of Food and Nutrition, Chung-Ang University, Anseong, Gyeonggi, 17546 Korea
| | - Sun-Young Lee
- 1Department of Food and Nutrition, Chung-Ang University, Anseong, Gyeonggi, 17546 Korea
| | - Ki-Hwan Park
- 2Department of Food Science and Technology, Chung-Ang University, Anseong, Gyeonggi, 17546 Korea
| |
Collapse
|
10
|
Kouyoumdzian NM, Mikusic NR, Cao G, Choi MR, Penna SD, Fernández BE, Toblli JE, Rosón MI. Adverse effects of tempol on hidrosaline balance in rats with acute sodium overload. Biotech Histochem 2017; 91:510-521. [PMID: 27849390 DOI: 10.1080/10520295.2016.1249029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
We studied the effects of tempol, an oxygen radical scavenger, on hydrosaline balance in rats with acute sodium overload. Male rats with free access to water were injected with isotonic (control group) or hypertonic saline solution (0.80 mol/l NaCl) either alone (Na group) or with tempol (Na-T group). Hydrosaline balance was determined during a 90 min experimental period. Protein expressions of aquaporin 1 (AQP1), aquaporin 2 (AQP2), angiotensin II (Ang II) and endothelial nitric oxide synthase (eNOS) were measured in renal tissue. Water intake, creatinine clearance, diuresis and natriuresis increased in the Na group. Under conditions of sodium overload, tempol increased plasma sodium and protein levels and increased diuresis, natriuresis and sodium excretion. Tempol also decreased water intake without affecting creatinine clearance. AQP1 and eNOS were increased and Ang II decreased in the renal cortex of the Na group, whereas AQP2 was increased in the renal medulla. Nonglycosylated AQP1 and eNOS were increased further in the renal cortex of the Na-T group, whereas AQP2 was decreased in the renal medulla and was localized mainly in the cell membrane. Moreover, p47-phox immunostaining was increased in the hypothalamus of Na group, and this increase was prevented by tempol. Our findings suggest that tempol causes hypernatremia after acute sodium overload by inhibiting the thirst mechanism and facilitating diuresis, despite increasing renal eNOS expression and natriuresis.
Collapse
Affiliation(s)
- N M Kouyoumdzian
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - Nl Rukavina Mikusic
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - G Cao
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - M R Choi
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - Sl Della Penna
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - B E Fernández
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - J E Toblli
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| | - M I Rosón
- a Cardiological Research Institute (ININCA), Scientific and Technological Research National Council (CONICET), University of Buenos Aires , Buenos Aires , Argentina
| |
Collapse
|
11
|
Lathrop K, Lucas J, Vacirca JL, Bhat G, Choi MR, Naughton M. Abstract OT1-02-10: A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-02-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the epidermal growth factor receptor (EGFR) family of tyrosine-kinase receptors, including EGFR (HER1/ErbB1/EGFR), HER2 (ErbB2), and HER4 (ErbB4), as well as HER receptor mutations. This, in turn, leads to inhibition of the proliferation of tumor cells that overexpress these receptors. It is well established that breast cancers are associated with a mutation in, or overexpression of, members of the EGFR receptor family. The primary objective of this Phase 2 study is to evaluate the Objective Response Rate (ORR) of poziotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive MBC. The secondary efficacy variables are Progression-Free Survival (PFS), Disease Control Rate (DCR), Overall Survival (OS), and Time to Progression (TTP).
Trial Design: This is a Phase 2, open-label, multicenter study to evaluate the efficacy, safety and tolerability of poziotinib in patients with HER2-positive MBC who have received at least 2 prior HER2- directed treatment regimens. Each treatment cycle is 21 days in duration. During each cycle, eligible patients receive 24 mg of poziotinib orally (as three 8-mg tablets) once daily for 14 days, followed by a 7 day treatment-free period.
Eligibility Criteria: Eligible patients are at least 18 years of age, have confirmed HER2 overexpression, adequate hematologic, renal and hepatic function, and have received at least 2 prior HER2-directed therapy regimens, including trastuzumab and trastuzumab emtansine (TDM-1). Patients are excluded if they have prior exposure to poziotinib, a history of congestive heart failure, left ventricular ejection fraction <50%, unable to take oral medications, or have conditions that cause malabsorption. A 30 day wash out period from previous chemotherapeutic or radiation therapies is required.
Statistical Methods: The purpose of this study is to evaluate the efficacy of poziotinib compared to the efficacy of other standard HER2-positive breast cancer treatments as reported in the literature. The ORR will be analyzed descriptively along with the 95% CI. The secondary efficacy variables will be analyzed descriptively.
Target Accrual: Approximately 70 patients. Enrollment began February 2016.
Contact Information: For more information or to refer a patient,
email: spi-poz-201@sppirx.com or fax: 1-949-398-9711.
Citation Format: Lathrop K, Lucas J, Vacirca JL, Bhat G, Choi MR, Naughton M. A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-02-10.
Collapse
Affiliation(s)
- K Lathrop
- The University of Texas Health Science Center at San Antonio, San Antonio, TX; Marin Cancer Care, Greenbrae, CA; North Shore Hematology/Oncology, East Satauket, NY; Spectrum Pharmaceuticals, Irvine, CA; Washington University, St Louis, MO
| | - J Lucas
- The University of Texas Health Science Center at San Antonio, San Antonio, TX; Marin Cancer Care, Greenbrae, CA; North Shore Hematology/Oncology, East Satauket, NY; Spectrum Pharmaceuticals, Irvine, CA; Washington University, St Louis, MO
| | - JL Vacirca
- The University of Texas Health Science Center at San Antonio, San Antonio, TX; Marin Cancer Care, Greenbrae, CA; North Shore Hematology/Oncology, East Satauket, NY; Spectrum Pharmaceuticals, Irvine, CA; Washington University, St Louis, MO
| | - G Bhat
- The University of Texas Health Science Center at San Antonio, San Antonio, TX; Marin Cancer Care, Greenbrae, CA; North Shore Hematology/Oncology, East Satauket, NY; Spectrum Pharmaceuticals, Irvine, CA; Washington University, St Louis, MO
| | - MR Choi
- The University of Texas Health Science Center at San Antonio, San Antonio, TX; Marin Cancer Care, Greenbrae, CA; North Shore Hematology/Oncology, East Satauket, NY; Spectrum Pharmaceuticals, Irvine, CA; Washington University, St Louis, MO
| | - M Naughton
- The University of Texas Health Science Center at San Antonio, San Antonio, TX; Marin Cancer Care, Greenbrae, CA; North Shore Hematology/Oncology, East Satauket, NY; Spectrum Pharmaceuticals, Irvine, CA; Washington University, St Louis, MO
| |
Collapse
|
12
|
Vacirca JL, Agajanian R, Papai Z, Horvath Z, Makharadze R, Ibrahim EN, Choi MR, Song T, Tedesco KL, McGregor K, Schwartzberg LS. Abstract P5-11-09: Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eflapegrastim is a distinct biologic that uses the innovative proprietary long-acting protein/peptide discovery technology (LAPSCOVERY™) and consists of a novel, modified recombinant human G-CSF conjugated to the Fc fragment of IgG4 via a polyethylene glycol linker. A Phase 2 study of 3 doses of eflapegrastim vs pegfilgrastim was conducted in breast cancer patients receiving docetaxel + cyclophosphamide (TC) chemotherapy.
Methods: This was an open-label, global, multicenter, dose-ranging study designed to compare the safety and efficacy of eflapegrastim relative to a fixed dose of pegfilgrastim as a concurrent active control. The study included 4 treatment arms: 3 dose levels of eflapegrastim (45 μg/kg, 135 μg/kg, and 270 μg/kg) vs pegfilgrastim (6 mg). The primary objective of the study was the Duration of Severe Neutropenia (DSN) during Cycle 1. The results for the primary objective, along with demographics and safety, were described in a previous presentation (SABCS 2015 P1-10-05). The secondary endpoints included DSN in Cycles 2-4, absolute neutrophil count (ANC) in Cycles 1-4, the overall incidences of febrile neutropenia (FN) and hospitalization rates.
Results: A total of 147 evaluable patients were enrolled. Patient and tumor characteristics were comparable across all 4 treatment arms. Median age was 59.0 years (range 32 to 77 years); most patients were <65 years (68%), Female (98%), and White (95%). The DSN for the 135 µg/kg and 270 µg/kg was non-inferior to pegfilgrastim during all cycles and the DSN for patients treated with 45 µg/kg was non-inferior during Cycles 2 and 3 (Table 1). The ANC was dose proportional across all 4 cycles. The incidence of FN and hospitalization rates was low in all arms and there were no significant differences between the Eflapegrastim and Pegfilgrastim Arms (Table 2).
Table 1. Duration of Severe Neutropenia in Cycles 2 to 4 of TC Chemotherapy by Treatment ArmDSN (Days)Eflapegrastim 45 μg/kg (N=39)Eflapegrastim 135 μg/kg (N=36)Eflapegrastim 270 μg/kg (N=36)Pegfilgrastim 6 mg (N=36)Cycle 2Difference with pegfilgrastim0.380.04-0.05NANon-Inferiority p-value0.001<0.001<0.001NACycle 3Difference with pegfilgrastim0.310.020.01NANon-Inferiority p-value0.002<0.001<0.001NACycle 4Difference with pegfilgrastim0.940.07-0.02NANon-Inferiority p-value0.781<0.001<0.001NADSN = Duration of Severe Neutropenia; NA = Not Applicable
Table 2. Incidence of Febrile Neutropenia and Hospitalizations Eflapegrastim 45 μg/kg (N=39)Eflapegrastim 135 μg/kg (N=36)Eflapegrastim 270 μg/kg (N=36)Pegfilgrastim 6 mg (N=36)Febrile NeutropeniaIncidence (%)3 (7.7%)1 (2.8%)1 (2.8%)2 (5.6%)Difference with Pegfilgrastim2.1 %-2.8%-2.8%NAp-value1.0001.0001.000NAHospitalizationsIncidence (%)3 (7.7%)3 (8.3%)1 (2.8%)5 (13.9%)Difference with Pegfilgrastim-6.2%-5.6%-11.1%NAp-value0.4690.7100.199NA
Conclusions: In breast cancer patients treated with TC, the non-inferiority of DSN of 135 µg/kg and 270 µg/kg eflapegrastim, compared to pegfilgrastim in Cycle 1, was sustained through Cycles 2-4 and the ANC profiles were comparable in Cycles 1-4. In addition, the overall incidence of FN and hospitalizations was comparable between the eflapegrastim arms and the pegfilgrastim arm.
Citation Format: Vacirca JL, Agajanian R, Papai Z, Horvath Z, Makharadze R, Ibrahim EN, Choi MR, Song T, Tedesco KL, McGregor K, Schwartzberg LS. Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-09.
Collapse
Affiliation(s)
- JL Vacirca
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - R Agajanian
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - Z Papai
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - Z Horvath
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - R Makharadze
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - EN Ibrahim
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - MR Choi
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - T Song
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - KL Tedesco
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - K McGregor
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - LS Schwartzberg
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| |
Collapse
|
13
|
Schwartzberg LS, Bharadwaj J, Peguero JA, Vacirca JL, Ibrahim EN, Bhat G, Choi MR, McGregor K, Agajanian R. Abstract OT1-01-11: Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-01-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eflapegrastim is a distinct biologic that uses an innovative, proprietary long-acting protein/peptide discovery technology (LAPSCOVERY™). Eflapegrastim consists of a novel, modified recombinant human G-CSF conjugated to the Fc fragment of IgG4 via a polyethylene glycol linker to produce a new, longer-acting G-CSF with a potentially unique distribution to areas rich in Fc receptors including its site of action in the bone marrow. A successful dose-finding Phase 2 trial including a pegfilgrastim control arm established the dose for a Phase 3 non-inferiority trial.
Trial Design: This is a randomized, open-label, active-controlled, multinational, multicenter, Phase 3 study comparing the efficacy and safety of eflapegrastim to pegfilgrastim. Patients (n=580) will be randomized in a 1:1 ratio to receive either eflapegrastim (equivalent to 3.6 mg G-CSF) or pegfilgrastim (equivalent to 6.0 mg G-CSF) once per chemotherapy cycle (up to 4 cycles), approximately 24 hours after chemotherapy. The primary endpoint is to compare the efficacy of a single dose of eflapegrastim with pegfilgrastim in patients with ESBC receiving TC, as measured by the Duration of Severe Neutropenia (DSN) in Cycle 1. Key secondary objectives include Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1; Depth of ANC Nadir in Cycle 1; incidence of Febrile Neutropenia. Safety and pharmacokinetics will also be assessed.
Eligibility Criteria: This study is enrolling histologically confirmed ESBC patients who are: eligible to receive adjuvant or neoadjuvant TC chemotherapy; at least 18 years of age, with adequate hematologic, renal and hepatic function. Patients will be excluded if they have: active concurrent malignancy or life-threatening disease; a known sensitivity or previous reaction to E. coli derived products or any of the products to be administered during study participation; concurrent adjuvant cancer therapy; locally recurrent/metastatic or contralateral breast cancer; previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development prior to the administration of study drug; bone marrow or hematopoietic stem cell transplant or radiation therapy prior to enrollment, or are pregnant or breast-feeding.
Statistical Methods: The goal of this study is to demonstrate non-inferiority. For the Primary Efficacy Analysis, the mean DSN in Cycle 1 will be compared between the eflapegrastim and pegfilgrastim treatment arms. A 2-sided 95% confidence interval (CI) of the difference between the mean DSN of the eflapegrastim arm and the mean DSN of the pegfilgrastim arm will be calculated using bootstrap resampling with treatment as the only stratification factor. For the Secondary Efficacy Analyses, the results will each be summarized by treatment arm and cycle. The two-sided 95% CI for the difference between the treatment arms will be calculated.
Target Accrual: Approximately 580 patients. Enrollment began January 2016.
Contact Information: Spectrum Pharmaceuticals. advance@sppirx.com.
Citation Format: Schwartzberg LS, Bharadwaj J, Peguero JA, Vacirca JL, Ibrahim EN, Bhat G, Choi MR, McGregor K, Agajanian R. Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-01-11.
Collapse
Affiliation(s)
- LS Schwartzberg
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - J Bharadwaj
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - JA Peguero
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - JL Vacirca
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - EN Ibrahim
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - G Bhat
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - MR Choi
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - K McGregor
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| | - R Agajanian
- West Cancer Center, Memphis, TN; Oncology Consultants, Houston, TX; North Shore Hematology/Oncology Associates, East Setauket, NY; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; Samaritan Hematology and Oncology Associates, Corvallis, OR; The Oncology Institute of Hope and Innovation, Downey, CA; Pacific Cancer Medical Center, Anaheim, CA
| |
Collapse
|
14
|
Verleker AP, Shaffer M, Fang Q, Choi MR, Clare S, Stantz KM. Optical dosimetry probes to validate Monte Carlo and empirical-method-based NIR dose planning in the brain: publisher's note. Appl Opt 2017; 56:1131. [PMID: 28158124 PMCID: PMC5497296 DOI: 10.1364/ao.56.001131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
This note points out additional funding information that was not added to [Appl. Opt.55, 9875 (2016)APOPAI0003-693510.1364/AO.55.009875] during production.
Collapse
Affiliation(s)
- Akshay Prabhu Verleker
- School of Health Sciences, Purdue University, 550 Stadium Mall
Drive, West Lafayette, Indiana 47907, USA
| | - Michael Shaffer
- School of Health Sciences, Purdue University, 550 Stadium Mall
Drive, West Lafayette, Indiana 47907, USA
| | - Qianqian Fang
- Department of Bioengineering, Northeastern University, 360
Huntington Avenue, Boston, Massachusetts 02115, USA
| | - Mi-Ran Choi
- Department of Surgery, Feinberg School of Medicine, Northwestern
University, 303 East Superior Street, Chicago, Illinois 60611, USA
| | - Susan Clare
- Department of Surgery, Feinberg School of Medicine, Northwestern
University, 303 East Superior Street, Chicago, Illinois 60611, USA
| | - Keith M. Stantz
- School of Health Sciences, Purdue University, 550 Stadium Mall
Drive, West Lafayette, Indiana 47907, USA
| |
Collapse
|
15
|
Verleker AP, Shaffer M, Fang Q, Choi MR, Clare S, Stantz KM. Optical dosimetry probes to validate Monte Carlo and empirical-method-based NIR dose planning in the brain. Appl Opt 2016; 55:9875-9888. [PMID: 27958483 PMCID: PMC5483856 DOI: 10.1364/ao.55.009875] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A three-dimensional photon dosimetry in tissues is critical in designing optical therapeutic protocols to trigger light-activated drug release. The objective of this study is to investigate the feasibility of a Monte Carlo-based optical therapy planning software by developing dosimetry tools to characterize and cross-validate the local photon fluence in brain tissue, as part of a long-term strategy to quantify the effects of photoactivated drug release in brain tumors. An existing GPU-based 3D Monte Carlo (MC) code was modified to simulate near-infrared photon transport with differing laser beam profiles within phantoms of skull bone (B), white matter (WM), and gray matter (GM). A novel titanium-based optical dosimetry probe with isotropic acceptance was used to validate the local photon fluence, and an empirical model of photon transport was developed to significantly decrease execution time for clinical application. Comparisons between the MC and the dosimetry probe measurements were on an average 11.27%, 13.25%, and 11.81% along the illumination beam axis, and 9.4%, 12.06%, 8.91% perpendicular to the beam axis for WM, GM, and B phantoms, respectively. For a heterogeneous head phantom, the measured % errors were 17.71% and 18.04% along and perpendicular to beam axis. The empirical algorithm was validated by probe measurements and matched the MC results (R2>0.99), with average % error of 10.1%, 45.2%, and 22.1% relative to probe measurements, and 22.6%, 35.8%, and 21.9% relative to the MC, for WM, GM, and B phantoms, respectively. The simulation time for the empirical model was 6 s versus 8 h for the GPU-based Monte Carlo for a head phantom simulation. These tools provide the capability to develop and optimize treatment plans for optimal release of pharmaceuticals in the treatment of cancer. Future work will test and validate these novel delivery and release mechanisms in vivo.
Collapse
Affiliation(s)
- Akshay Prabhu Verleker
- School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, Indiana 47907, USA
| | - Michael Shaffer
- School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, Indiana 47907, USA
| | - Qianqian Fang
- Department of Bioengineering, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, USA
| | - Mi-Ran Choi
- Department of Surgery, Feinberg School of Medicine, Northwestern University 303 East Superior Street, Chicago, Illinois 60611, USA
| | - Susan Clare
- Department of Surgery, Feinberg School of Medicine, Northwestern University 303 East Superior Street, Chicago, Illinois 60611, USA
| | - Keith M. Stantz
- School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, Indiana 47907, USA
| |
Collapse
|
16
|
Clare SE, Gupta A, Choi M, Ranjan M, Lee O, Wang J, Ivancic DZ, Kim JJ, Khan SA. Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes. BMC Cancer 2016; 16:326. [PMID: 27215412 PMCID: PMC4878043 DOI: 10.1186/s12885-016-2355-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 05/11/2016] [Indexed: 12/15/2022] Open
Abstract
Background The synthesis of specific, potent progesterone antagonists adds potential agents to the breast cancer prevention and treatment armamentarium. The identification of individuals who will benefit from these agents will be a critical factor for their clinical success. Methods We utilized telapristone acetate (TPA; CDB-4124) to understand the effects of progesterone receptor (PR) blockade on proliferation, apoptosis, promoter binding, cell cycle progression, and gene expression. We then identified a set of genes that overlap with human breast luteal-phase expressed genes and signify progesterone activity in both normal breast cells and breast cancer cell lines. Results TPA administration to T47D cells results in a 30 % decrease in cell number at 24 h, which is maintained over 72 h only in the presence of estradiol. Blockade of progesterone signaling by TPA for 24 h results in fewer cells in G2/M, attributable to decreased expression of genes that facilitate the G2/M transition. Gene expression data suggest that TPA affects several mechanisms that progesterone utilizes to control gene expression, including specific post-translational modifications, and nucleosomal organization and higher order chromatin structure, which regulate access of PR to its DNA binding sites. Conclusions By comparing genes induced by the progestin R5020 in T47D cells with those increased in the luteal-phase normal breast, we have identified a set of genes that predict functional progesterone signaling in tissue. These data will facilitate an understanding of the ways in which drugs such as TPA may be utilized for the prevention, and possibly the therapy, of human breast cancer. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2355-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Susan E Clare
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - Akash Gupta
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - MiRan Choi
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - Manish Ranjan
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - Oukseub Lee
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - Jun Wang
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - David Z Ivancic
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA
| | - J Julie Kim
- Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA.
| | - Seema A Khan
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Lurie 4-111, Chicago, IL, 60611, USA.
| |
Collapse
|
17
|
Lee O, Choi MR, Christov K, Ivancic D, Khan SA. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation. Cancer Lett 2016; 376:310-7. [PMID: 27080304 DOI: 10.1016/j.canlet.2016.04.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Revised: 04/05/2016] [Accepted: 04/06/2016] [Indexed: 12/12/2022]
Abstract
PURPOSE Blockade of the progestogen-progesterone receptor (PR) axis is a novel but untested strategy for breast cancer prevention. We report preclinical data evaluating telapristone acetate (TPA), ulipristal acetate (UPA), and mifepristone. METHODS Tumors were induced with medroxyprogesterone acetate (MPA) plus 7,12-dimethylbenz[a]anthracene (DMBA) in mice, and MPA or progesterone plus N-methyl-N-nitrosourea (MNU) in rats. Mammary gland histology, tumor incidence, latency, multiplicity, burden and histology were evaluated, along with immunohistochemical labeling of pHH3 (proliferation), CD34 (angiogenesis), and estrogen and progesterone receptors (ER and PR). A concentration gradient of TPA, UPA, and mifepristone was tested for growth inhibition of T47D spheroids. RESULTS In mouse mammary glands, no tumors formed, but TPA opposed the pro-hyperplastic effects of MPA (p = 0.002). In rats, TPA decreased tumor incidence (p = 0.037 for MPA + TPA vs. MPA, and p = 0.032 for progesterone + TPA vs. progesterone) and tumor burden (p = 0.042 for progesterone + TPA vs. progesterone), with significant decreases in pHH3 and CD34 positive cells. TPA and UPA were superior to mifepristone in growth inhibition of T47D spheroids. CONCLUSION TPA has consistent anti-tumorigenic effects in several models, which are accompanied by decreases in cell proliferation, angiogenesis, and hormone receptor expression.
Collapse
Affiliation(s)
- Oukseub Lee
- Department of Surgery, Northwestern University, Chicago, IL, USA
| | - Mi-Ran Choi
- Department of Surgery, Northwestern University, Chicago, IL, USA
| | - Konstantin Christov
- Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA
| | - David Ivancic
- Department of Surgery, Northwestern University, Chicago, IL, USA
| | - Seema A Khan
- Department of Surgery, Northwestern University, Chicago, IL, USA; Feinberg College of Medicine, The Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
| |
Collapse
|
18
|
Schwartzberg L, Vacirca JL, Hager SJ, Adoo CS, Ibrahim EN, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R. Abstract OT3-02-13: Randomized phase 3 study of a novel, long-acting G-CSF (SPI-2012) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-02-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: SPI-2012 is a distinct biologic that uses the innovative, proprietary long-acting protein/peptide discovery technology (LAPSCOVERY™) to enhance the activity of G-CSF. SPI-2012 consists of a novel, modified recombinant human G-CSF conjugated to the Fc fragment of IgG4 via a polyethylene glycol linker to produce a new, more potent, longer-acting G-CSF with a potentially unique distribution to areas rich in Fc receptors. The primary endpoint of this Phase 3 study is to compare the efficacy of a single dose of SPI-2012 with pegfilgrastim in patients with early-stage breast cancer (ESBC) receiving TC chemotherapy, as measured by the Duration of Severe Neutropenia (DSN) in Cycle 1. Key secondary objectives include the comparison of SPI-2012 with pegfilgrastim during Cycle 1 in: Time to Absolute Neutrophil Count (ANC) Recovery; Depth of ANC Nadir and Incidence of Febrile Neutropenia. Safety and pharmacokinetics will also be assessed.
Trial Design: This is a randomized, open-label, active-controlled, multicenter study comparing the efficacy and safety of SPI-2012 to pegfilgrastim. Patients (n=506) will be randomized in a 1:1 ratio to receive either SPI-2012 (equivalent to 3.6 mg G-CSF) or pegfilgrastim (equivalent to 6.0 mg G-CSF) once per chemotherapy cycle (up to 4 cycles), approximately 24 hrs after chemotherapy.
Eligibility Criteria: This study will enroll histologically confirmed ESBC patients who are eligible to receive adjuvant or neoadjuvant TC chemotherapy and at least 18 years of age, with adequate hematologic, renal and hepatic function. Patients will be excluded if they have active concurrent malignancy or life-threatening disease; a known sensitivity or previous reaction to E. coli derived products or any of the products to be administered during study participation; concurrent adjuvant cancer therapy; locally recurrent/metastatic or contralateral breast cancer; previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development prior to the administration of study drug; bone marrow or hematopoietic stem cell transplant or radiation therapy prior to enrollment or are pregnant or breast-feeding.
Statistical Methods: The goal of the study is to demonstrate non-inferiority of SPI-2012 to pegfilgrastim. For the Primary Efficacy Analysis, the mean DSN in Cycle 1 will be compared between the SPI-2012 and pegfilgrastim treatment arms. A 2-sided 95% confidence interval (CI) of the difference between the mean DSN of the SPI-2012 arm and the mean DSN of the pegfilgrastim arm will be calculated using bootstrap resampling with treatment as the only stratification factor. For the Secondary Efficacy Analyses, the results will each be summarized by treatment arm and Cycle. The two-sided 95% CI for the difference between the treatment arms will be calculated.
Target Accrual: Approximately 506 pts.
Citation Format: Schwartzberg L, Vacirca JL, Hager SJ, Adoo CS, Ibrahim EN, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R. Randomized phase 3 study of a novel, long-acting G-CSF (SPI-2012) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-02-13.
Collapse
Affiliation(s)
- L Schwartzberg
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - JL Vacirca
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - SJ Hager
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - CS Adoo
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - EN Ibrahim
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - G Bhat
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - MR Choi
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - LF Allen
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - KL Tedesco
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| | - R Agajanian
- The West Clinic, Memphis, TN; North Shore Hematology/Oncology Associates, East Setauket, NY; California Cancer Associates for Research and Excellence, Fresno, CA; Arizona Center for Cancer Care, Glendale, AZ; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation, Downey, CA
| |
Collapse
|
19
|
Vacirca JL, Chan A, Mezei K, Adoo CS, Papai Z, McGregor K, Okera M, Horvath Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Ghazal H, Rostom M, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R, Lang I. Abstract P1-10-05: Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with breast cancer (BC) treated with (Neo) adjuvant chemotherapy with docetaxel + cyclophosphamide (TC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: SPI-2012 is a distinct biologic that uses the innovative proprietary long-acting protein/peptide discovery technology (LAPSCOVERY™) to enhance the activity of G-CSF. SPI-2012 consists of a novel, modified recombinant human G-CSF conjugated to the Fc fragment of IgG4 via a polyethylene glycol linker to produce a new, more potent, longer-acting G-CSF with a potentially unique distribution to areas rich in Fc receptors. To assess the effect of SPI-2012 in supporting patients with breast cancer receiving myelosuppressive chemotherapy with TC, we conducted a randomized Phase 2 study of 3 SPI-2012 doses versus pegfilgrastim.
Methods: This was an open-label, global, multicenter, dose-ranging study designed to compare the safety and efficacy of SPI-2012 relative to a fixed, standard dose of pegfilgrastim as a concurrent active control. The study included 4 treatment arms: 3 dose levels of SPI-2012 (45 μg/kg, 135 μg/kg, and 270 μg/kg) vs pegfilgrastim (6 mg,). The primary objective of the study was the Duration of Severe Neutropenia (DSN) during Cycle 1 in patients with BC who received adjuvant or neoadjuvant TC chemotherapy.
Results: A total of 147 evaluable patients were enrolled. Patient and tumor characteristics were comparable across all 4 treatment arms. Mean age was 58.2 years (range 32 to 77 years); most patients were <65 years (68%), female (98%) and white (95%). The study met its primary endpoint with DSN in patients treated in the 135 µg/kg and 270 µg/kg SPI-2012 treatment arms in Cycle 1 showing non-inferiority to the DSN in patients treated with pegfilgrastim (p=0.002 and p<0.001, respectively). In addition, superiority was demonstrated in patients treated with 270 µg/kg SPI-2012 compared to pegfilgrastim (p=0.023). Non-inferiority in DSN was also observed in Cycles 2 to 4 in both the 135 µg/kg and 270 µg/kg SPI-2012 treatment arms compared to pegfilgrastim.
Duration of Severe Neutropenia in Cycle 1 of TC chemotherapy by Treatment Arm 45 μg/kg SPI-2012 (N=39) 135 μg/kg SPI-2012 (N=36) 270 μg/kg SPI-2012 (N=36)Pegfilgrastim (N=36)DSN Mean (SD)(days)1.03 (1.5)0.44 (1.3)0.03 (0.2)0.31 (0.8)Difference with pegfilgrastim0.720.14-0.28NANon-inferiority p-value0.2960.002<0.001NASuperiority p-value0.0060.5280.023NASD=Standard Deviation; NA=Not Applicable
The common treatment-emergent adverse events observed in ≥20% of patients were similar across all 4 study arms with similar or lower incidence in the SPI-2012 treatment arms, and included fatigue, nausea, alopecia, diarrhea, and bone pain.
Conclusions: All doses of SPI-2012 administered in this Phase 2 study were well tolerated, and no new or significant dose-related toxicities were observed. Most reported adverse events were mild and similar to those previously reported in clinical trials with filgrastim and pegfilgrastim in patients receiving myelosuppressive chemotherapy. In Cycle 1, the 135 µg/kg dose of SPI-2012 was non-inferior compared to pegfilgrastim, and the 270 µg/kg dose was superior in terms of DSN. Additional efficacy and safety data for SPI-2012 will be collected in planned Phase 3 clinical trials.
Citation Format: Vacirca JL, Chan A, Mezei K, Adoo CS, Papai Z, McGregor K, Okera M, Horvath Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Ghazal H, Rostom M, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R, Lang I. Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with breast cancer (BC) treated with (Neo) adjuvant chemotherapy with docetaxel + cyclophosphamide (TC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-05.
Collapse
Affiliation(s)
- JL Vacirca
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - A Chan
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - K Mezei
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - CS Adoo
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - Z Papai
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - K McGregor
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - M Okera
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - Z Horvath
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - L Landherr
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - J Hanslik
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - SJ Hager
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - EN Ibrahim
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - H Ghazal
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - M Rostom
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - G Bhat
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - MR Choi
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - LF Allen
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - KL Tedesco
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - R Agajanian
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - I Lang
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| |
Collapse
|
20
|
Sauder CA, Koziel JE, Choi M, Herbert BS, Clare SE. Abstract B48: Clues to the causes of the abundance of triple-negative breast cancer in women of African descent. Cancer Epidemiol Biomarkers Prev 2015. [DOI: 10.1158/1538-7755.disp14-b48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Background: Triple negative breast cancer (TNBC) is over-represented in indigenous African women and in women of African descent. The majority of women diagnosed with breast cancer in Nigeria, Uganda and Kenya have TNBC. Studies of TNBC in the US consistently report the percentage of TNBC to be 10-24% greater in African-Americans (AA) than in Caucasians (C). The abundance of TNBCs in both African and African-American women has yet to be explained and the incidence rates suggest that there may be a genetic predisposition to this particularly aggressive form of breast cancer.
Methods: Epithelial cell lines were established from normal, healthy breast tissue donated to the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center. Six cell lines from AA donors were matched on the basis of age, menopausal status and Gail-risk score to six cell lines from C donors. RNA was extracted from the cells and gene expression assayed using the Illumina HumanWG6 v3 chip. Significant differences in gene expression were identified using PADE (PAirwise Differential Expression; Expression Analysis, Durham, NC).
Results: 1552 genes were differentially expressed (p≤ 0.05). The largest number of genes over-expressed in AAs mapped to the long arm of chromosome 1. Copy number gains have been observed in this region in multiple TNBC data sets. Many of these genes are in the 1q21 region, a region frequently rearranged in epithelial tumors as well as soft tissue and bone. Analysis of differentially expressed genes using MetaCore from Thomson Reuters revealed that the over-expressed genes are responsible for skin development, cell adhesion/cell junctions, and functions of the innate immune system. Pattern recognition is in the vanguard of the innate immune system. The pattern recognition pathways mediated by RAGE (receptor for advanced glycation end products) and the Toll-like receptors are activated in the normal AA epithelium. The expression of genes in these pathways, specifically S100A12, S100A8, S110A9, and TLR5, is known to increase in the presence of Salmonella and Shigella. MDA5 recognizes rotavirus infection. LYST and DUSP4 are active in the control of Leishmania infection. LCN2 disrupts iron acquisition, which protects against a number of pathogens including Salmonella, Klebsiella and mycobacteria.
Conclusions: The results of the above gene expression analysis are best understood in light of our recently published findings using these same cells (Sauder et al, BMC Cell Biology, 2014). Epithelial cells grown from mammary explant culture are basal-like and phenotypically plastic. They can assume a wide range of cell types depending on the cues provided by the microenvironment. When grown in basement membrane matrix or on human dermal fibroblasts, these cells produce a stratified squamous epithelium. Although the cells used for the gene expression analysis were grown in plastic tissue culture flasks and grew as a monotonous monolayer, the data suggest that they are, to some extent, transcriptionally “squamous”. For example, they express involucrin and the genes that code for the corneodesmosome proteins: corneodesmin, desmoglein and desmocollin.
The skin of humans living in sub-Saharan Africa has evolved to provide optimal barrier protection. It specifically protects against water loss and, pathogenic microorganisms and parasites. Mammary glands are ectodermal appendages of the epithelium and they may share similar immune defense mechanisms. The increased expression of genes involved in innate immunity in AA breast epithelial cells is of significant interest. We hypothesize that a subclinical, chronic inflammatory state is incited within basal breast cells in response to a pathogen that is endemic to Africa and overrepresented in low income communities in the US. This persistent and unresolved innate immunity predates the development of TNBC and can thus participate in its initiation and promotion.
Citation Format: Candice A.M. Sauder, Jillian E. Koziel, MiRan Choi, Brittney-Shea Herbert, Susan E. Clare. Clues to the causes of the abundance of triple-negative breast cancer in women of African descent. [abstract]. In: Proceedings of the Seventh AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 9-12, 2014; San Antonio, TX. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2015;24(10 Suppl):Abstract nr B48.
Collapse
Affiliation(s)
| | | | - MiRan Choi
- 3Feinberg School of Medicine, Northwestern University, Chicago, IL
| | | | - Susan E. Clare
- 3Feinberg School of Medicine, Northwestern University, Chicago, IL
| |
Collapse
|
21
|
Choi MR, Do LT, Chung YH, Yoo H, Yu R. Antioxidative Activity of Platinum Nanocolloid and Its Protective Effect Against Chemical-Induced Hepatic Cellular Damage. J Nanosci Nanotechnol 2015; 15:5571-5576. [PMID: 26369119 DOI: 10.1166/jnn.2015.10468] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Oxidative stress, a major cause of cellular injuries, is closely associated with a variety of chronic diseases such as cancer, liver diseases, degenerative brain disease and aging. In this study, we investigated antioxidant properties of platinum nanocolloid (PNC) against various oxidative stress conditions in vitro/in vivo by treating PNC on liver cell or tissue. Antioxidant activities of the PNC were determined by measuring quenching capacity on reactive oxygen species and its protective action against hydrogen peroxide or CCl4-induced oxidative cellular damage in HepG2 cell or liver tissue of mice. In vitro study, PNC markedly suppressed the production H2O2, ·OH, α,α-diphenyl-β-picrylhydrazyl radical and nitric oxide in a dose-dependent manner. PNC also inhibited hydrogen peroxide-induced oxidative cellular damage in HepG2 hepatocytes. In vivo study with mice, PNC reduced hepatic lipid peroxidation and CCl4 induced toxicity. Our results support that platinum nanocolloid has antioxidant activities and protects hepatic cellular oxidative damage. Thus platinum nanocolloid may have a potential to be used as an antioxidant supplement.
Collapse
|
22
|
Shidfar A, Liu L, Parini V, Choi M, Ivancic D, Sullivan ME, Gursel DB, Khan SA, Wang J. Abstract 1985: PBX1 regulated lipid metabolism gene expression and epithelial-mesenchymal transition independent of estrogen receptor. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Pre-B-cell leukemia homeobox-1 (PBX1) is a member of the three amino acid loop extension (TALE) family of homeodomain proteins that bind to DNA and regulate gene transcription by forming heterodimeric transcription complexes with Meis and Prep1. PBX1 is involved in cell fate determination during organogenesis and contributes to oncogenic activity in breast cancer. As a pioneer factor, PBX1 was found to drive ER signaling in ER+ breast cancer by remodeling the chromatin and increasing DNA accessibility. But the role of PBX1 in benign breast and ER- cancer cells is not clear. In our previous studies, we identified and validated that the expression of a set of lipid metabolism genes was higher in the contralateral breast of ER- tumor. Bioinformatic analysis on lipid metabolism gene promoter regions and revealed that PBX1 may act as a potential transcription factor to co-regulate those genes. In this study, we further investigate the function of PBX1 in ER- cells.
Methods: Among the ER- cell lines, we infected cell lines expressing low endogenous PBX1 (MCF10A and MDA-MB-231) with PBX1 gene in lentiviral vector. We also infected cell lines expressing high endogenous PBX1 (MDA-MB-453 and SK-BR-3) with PBX1-shRNA to knockdown PBX1. The expression of lipid metabolism genes was detected by qRT-PCR. Markers for epithelial-to-mesenchymal transition (EMT) including E-cadherin, vimentin, β-catenin and α-SMA were detected using Western blot. The effects of overexpression or knock-down of PBX1 on proliferation, migration, and invasion were measured using IncuCyte live cell imaging system. The expression of PBX1 protein was measured in benign contralateral breast and in the matching tumor using mmnunohistochemistry.
Results: Over-expression of PBX1 in ER- cell lines (MCF10A and MDA-MB-231) up-regulated lipid metabolism genes and promoted cell migration and invasion by inducing EMT (increased vimentin and decreased E-cadherin and β-catenin). In contrast, knocking-down PBX1 using shRNA in ER- cell lines (MDA-MB-453 and SK-BR-3) suppressed lipid metabolism gene expression. PBX1 was more highly expressed in benign tissues associated with ER- tumors compared to ER+ tumors. In tumor tissue, on the contrary, ER+ tumors shower higher PBX1 expression levels than ER- tumors.
Conclusion: PBX1 is a master regulator of lipid metabolism genes. PBX1 promoted cell migration and invasion by inducing EMT. PBX1 may play different roles and interact with different co-factors in ER+ tumors and in benign tissues associated with ER- tumors.
Citation Format: Ali Shidfar, Liannian Liu, Vamsi Parini, MiRan Choi, David Ivancic, Megan E. Sullivan, Demirkan B. Gursel, Seema A. Khan, Jun Wang. PBX1 regulated lipid metabolism gene expression and epithelial-mesenchymal transition independent of estrogen receptor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1985. doi:10.1158/1538-7445.AM2015-1985
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Jun Wang
- Northwestern University, Chicago, IL
| |
Collapse
|
23
|
Baptiste D, Choi M, Wang Z, Liu Y, Radovich M, Clare SE. Abstract P4-13-01: Trancriptome sequencing of the hisologicaly normal breast epithelium of BRCA mutation carriers. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p4-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Meaningful progress in the prevention of breast cancer is unlikely until the risk of the development of breast cancer is translated into specific, quantifiable molecular alterations. Among those women at the greatest risk are BRCA mutations carriers: 55 to 65% of women who inherit a deleterious BRCA1 mutation and approximately 45 % who inherit a deleterious BRCA2 mutation will develop breast cancer by age 70 years. The purpose of this study was to identify the earliest transcriptional alterations present by examining the histologically normal breast epithelia of BRCA mutation carriers.
Methods: Epithelia were microdissected and the RNA isolated from the histologically normal breast of 16 frozen tissue cores from known BRCA mutation carriers, who were donors to the Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center. RNA-sequencing was carried out using the Life Technologies SOLiD XL 5500 Platform. RPKM gene expression values from the BRCA specimens and from Komen normal breast epithelium (controls; Pardo et al, Breast Cancer Research, 2014) were merged, quantile normalized, and batch effect corrected. Normalization and differential gene expression was performed using EdgeR v2.11
Results: 6583 RNAs were differentially expressed with the false discovery rate set at 0.1.
1. DNA damage is signaled by a tripartite system that includes kinases, phosphatases and proteins with modular domains, e.g., the BRCA 1 C-terminal (BRCT), that recognize phosphorylated linear motifs in other proteins. Several BRCT domains recognize motifs phosphorylated by kinases that are activated by DNA damage. To identify the proteins active in DNA damage signaling, Monteiro and colleagues generated a protein-protein interaction map for seven proteins with tandem BRCT (Cell Signaling, 2012). A significant proportion of the genes with decreased expression in our data set encode proteins that have been identified in this network.
2. Two of the top biological processes affected by the BRCA mutations in the histologically normal breast tissue are translation, and cellular protein metabolism.
3. There was significantly less expression of genes associated with other hereditary cancer syndromes inducing the genes responsible for Lynch Syndrome: MHL1, MHS2, MSH6 and PMS2; and the multiple endocrine neoplasia genes RET and MEN1.
4. High grade serous carcinoma of the ovary, the histologic subtype associated with BRCA mutation, may originate in the distal Fallopian tube. The list of differentially expressed genes from microdissected breast epithelia was compared with that derived from gene array profiling of microdissected Fallopian tube epithelium from histologically normal BRCA1 mutation carriers and controls. 795 genes were common to both gene sets, of which 354 were regulated similarly, i.e., increased or decreased. MetaCore data analysis revealed CREB1 and c-Myc as the most important regulatory factors in the similar dataset.
Conclusions: There are significant transcription alterations in the histologically normal breast tissue of BRCA mutation carriers. These data will have to be corroborated at the protein level and functional level. Once substantiated, they have potential to stratify risk and to serve as targets for prevention.
Citation Format: Dadrie Baptiste, MiRan Choi, Zhiping Wang, Yunlong Liu, Milan Radovich, Susan E Clare. Trancriptome sequencing of the hisologicaly normal breast epithelium of BRCA mutation carriers [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-13-01.
Collapse
Affiliation(s)
| | - MiRan Choi
- 2Feinberg School of Medicine, Northwestern University
| | | | | | | | - Susan E Clare
- 2Feinberg School of Medicine, Northwestern University
| |
Collapse
|
24
|
Kim DH, Choi MR, Hong JE, Lee JY, Kwon HS, Jang SH, Kim EJ. A functional egg yolk powder containing an antibody against Niemann-Pick C1-like1 (NPC1L1) lowers cholesterol levels in high cholesterol diet induced hypercholesterolemic SD rats. Food Sci Biotechnol 2015. [DOI: 10.1007/s10068-015-0029-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
25
|
Halder D, Mandal C, Lee BH, Lee JS, Choi MR, Chai JC, Lee YS, Jung KH, Chai YG. PCDHB14- and GABRB1-like nervous system developmental genes are altered during early neuronal differentiation of NCCIT cells treated with ethanol. Hum Exp Toxicol 2015; 34:1017-27. [PMID: 25566775 DOI: 10.1177/0960327114566827] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Ethanol (EtOH) exposure during embryonic development causes dysfunction of the central nervous system (CNS). Here, we examined the effects of chronic EtOH on gene expression during early stages of neuronal differentiation. Human embryonic carcinoma (NCCIT) cells were differentiated into neuronal precursors/lineages in the presence or absence of EtOH and folic acid. Gene expression profiling and pathway analysis demonstrated that EtOH deregulates many genes and pathways that are involved in early brain development. EtOH exposure downregulated several important genes, such as PCDHB14, GABRB1, CTNND2, NAV3, RALDH1, and OPN5, which are involved in CNS development, synapse assembly, synaptic transmission, and neurotransmitter receptor activity. GeneGo pathway analysis revealed that the deregulated genes mapped to disease pathways that were relevant to fetal alcohol spectrum disorders (FASD, such as neurotic disorders, epilepsy, and alcohol-related disorders). In conclusion, these findings suggest that the impairment of the neurological system or suboptimal synapse formation resulting from EtOH exposure could underlie the neurodevelopmental disorders in individuals with FASD.
Collapse
Affiliation(s)
- D Halder
- Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - C Mandal
- Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - B H Lee
- Department of Psychiatry, Gangnam Eulji Hospital, Eulji University, Seoul, Republic of Korea KARF Hospital, the Korean Alcohol Research Foundation, Goyang, Republic of Korea
| | - J S Lee
- KARF Hospital, the Korean Alcohol Research Foundation, Goyang, Republic of Korea
| | - M R Choi
- Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - J C Chai
- Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - Y S Lee
- Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - K H Jung
- Institute of Natural Science and Technology, Hanyang University, Ansan, Republic of Korea
| | - Y G Chai
- Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea Department of Nanobiotechnology, Hanyang University, Seoul, Republic of Korea
| |
Collapse
|
26
|
Choi MR, Jeong SG, Liu Q, Ban GH, Lee SY, Park JW, Kang DH. Effect of thiamine dilaurylsulfate against Escherichia coli O157:H7, Salmonella Typhimurium, Listeria monocytogenes and Bacillus cereus spores in custard cream. Lebensm Wiss Technol 2015. [DOI: 10.1016/j.lwt.2014.09.040] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Choi MR, Lee MY, Hong JE, Kim JE, Lee JY, Kim TH, Chun JW, Shin HK, Kim EJ. Rubus coreanus Miquel Ameliorates Scopolamine-Induced Memory Impairments in ICR Mice. J Med Food 2014; 17:1049-56. [DOI: 10.1089/jmf.2013.3004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Mi-Ran Choi
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, Chuncheon, Korea
| | - Min Young Lee
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, Chuncheon, Korea
| | - Ji Eun Hong
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, Chuncheon, Korea
| | - Jeong Eun Kim
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, Chuncheon, Korea
| | - Jae-Yong Lee
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, Chuncheon, Korea
- Department of Biochemistry, College of Medicine, Hallym University, Chuncheon, Korea
| | - Tae Hwan Kim
- Research and Development Center, Hitejinro Co. Ltd., Hongcheon, Korea
| | - Jang Woo Chun
- Research and Development Center, Hitejinro Co. Ltd., Hongcheon, Korea
| | | | - Eun Ji Kim
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, Chuncheon, Korea
| |
Collapse
|
28
|
Lee MG, Oh D, Choi MR, Chai YG, Kim SH, Oh DH, Choi J. NCAM140 and pCREB Expression after Tianeptine Treatment of SH-SY5Y Cells. Psychiatry Investig 2014; 11:313-8. [PMID: 25110505 PMCID: PMC4124191 DOI: 10.4306/pi.2014.11.3.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Revised: 10/04/2013] [Accepted: 10/23/2013] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE Antidepressants Modulate Neuronal Plasticity. Tianeptine, An Atypical Antidepressant, Might Be Involved In The Restoration Of Neuronal Plasticity; It Primarily Enhances The Synaptic Reuptake Of Serotonin. Ncam140 Is Involved In Neuronal Development Processes, Synaptogenesis And Synaptic Plasticity. We Investigated The Effect Of Tianeptine On The Expression Of Ncam140 And Its Downstream Signaling Molecule In The Human Neuroblastoma Cell Line Sh-sy5y. METHODS NCAM protein expression was measured in human neuroblastoma SH-SY5Y cells that were cultivated in serum-free media and treated with 0, 10, or 20 µM tianeptine for 6, 24, or 72 hours. NCAM140 expression in the tianeptine treatment group was confirmed by Western blot, and quantified through measurement of band intensity by absorbance. CREB and pCREB expression was identified after treatment with 20 µM tianeptine for 6, 24, and 72 hours by Western blot. RESULTS Compared to cells treated for 6 hours, cells treated with 0 or 10 µM tianeptine for 72 hours showed a significant increase in NCAM140 expression and cells treated with 20 µM tianeptine showed a significant increase after 24 and 72 hours. The pCREB level in cells treated with 20 µM tianeptine increased in time-dependent manner. CONCLUSION Our findings indicated that the tianeptine antidepressant effect may occur by induction of NCAM140 expression and CREB phosphorylation.
Collapse
Affiliation(s)
- Mi-gyung Lee
- Department of General Psychiatry, Seoul National Hospital, Seoul, Republic of Korea
- Cognitive Neuroscience and Schizophrenia Program, Nathan Kline Institute, Orangeburg, New York, USA
| | - Daeyoung Oh
- Department of Neuropsychiatry, College of Medicine, Hanyang University, Hanyang University Guri Hospital, Guri, Republic of Korea
| | - Mi-Ran Choi
- Division of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - Young-Gyu Chai
- Division of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
| | - Seok-Hyeon Kim
- Department of Neuropsychiatry and Mental Health Institute, College of Medicine, Hanyang University, Seoul, Republic of Korea
| | - Dong-Hoon Oh
- Department of Neuropsychiatry and Mental Health Institute, College of Medicine, Hanyang University, Seoul, Republic of Korea
| | - Joonho Choi
- Department of Neuropsychiatry, College of Medicine, Hanyang University, Hanyang University Guri Hospital, Guri, Republic of Korea
- Department of Neuropsychiatry and Mental Health Institute, College of Medicine, Hanyang University, Seoul, Republic of Korea
| |
Collapse
|
29
|
Sauder CAM, Koziel JE, Choi M, Fox MJ, Grimes BR, Badve S, Blosser RJ, Radovich M, Lam CC, Vaughan MB, Herbert BS, Clare SE. Phenotypic plasticity in normal breast derived epithelial cells. BMC Cell Biol 2014; 15:20. [PMID: 24915897 PMCID: PMC4066279 DOI: 10.1186/1471-2121-15-20] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 05/22/2014] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Normal, healthy human breast tissue from a variety of volunteer donors has become available for research thanks to the establishment of the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center (KTB). Multiple epithelial (K-HME) and stromal cells (K-HMS) were established from the donated tissue. Explant culture was utilized to isolate the cells from pieces of breast tissue. Selective media and trypsinization were employed to select either epithelial cells or stromal cells. The primary, non-transformed epithelial cells, the focus of this study, were characterized by immunohistochemistry, flow cytometry, and in vitro cell culture. RESULTS All of the primary, non-transformed epithelial cells tested have the ability to differentiate in vitro into a variety of cell types when plated in or on biologic matrices. Cells identified include stratified squamous epithelial, osteoclasts, chondrocytes, adipocytes, neural progenitors/neurons, immature muscle and melanocytes. The cells also express markers of embryonic stem cells. CONCLUSIONS The cell culture conditions employed select an epithelial cell that is pluri/multipotent. The plasticity of the epithelial cells developed mimics that seen in metaplastic carcinoma of the breast (MCB), a subtype of triple negative breast cancer; and may provide clues to the origin of this particularly aggressive type of breast cancer. The KTB is a unique biorepository, and the normal breast epithelial cells isolated from donated tissue have significant potential as new research tools.
Collapse
Affiliation(s)
- Candice AM Sauder
- Department of Surgery, Indiana University School of Medicine, 980 W. Walnut Street, Indianapolis, IN 46202, USA
| | - Jillian E Koziel
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W. Walnut Street, Indianapolis, IN 46202, USA
| | - MiRan Choi
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Chicago, IL 60611, USA
| | - Melanie J Fox
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W. Walnut Street, Indianapolis, IN 46202, USA
| | - Brenda R Grimes
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W. Walnut Street, Indianapolis, IN 46202, USA
| | - Sunil Badve
- Department of Pathology, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN 46202, USA
| | - Rachel J Blosser
- Department of Surgery, Indiana University School of Medicine, 980 W. Walnut Street, Indianapolis, IN 46202, USA
| | - Milan Radovich
- Department of Surgery, Indiana University School of Medicine, 980 W. Walnut Street, Indianapolis, IN 46202, USA
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W. Walnut Street, Indianapolis, IN 46202, USA
| | - Christina C Lam
- Department of Biology, University of Central Oklahoma, 100 North University Drive, Edmond, OK 73034, USA
| | - Melville B Vaughan
- Department of Biology, University of Central Oklahoma, 100 North University Drive, Edmond, OK 73034, USA
| | - Brittney-Shea Herbert
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W. Walnut Street, Indianapolis, IN 46202, USA
| | - Susan E Clare
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Chicago, IL 60611, USA
| |
Collapse
|
30
|
Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CAM, Doxey DK, Mathieson T, Hancock BA, Baptiste D, Atale R, Hickenbotham M, Zhu J, Glasscock J, Storniolo AMV, Zheng F, Doerge RW, Liu Y, Badve S, Radovich M, Clare SE. Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. Breast Cancer Res 2014; 16:R26. [PMID: 24636070 PMCID: PMC4053088 DOI: 10.1186/bcr3627] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Accepted: 03/10/2014] [Indexed: 12/12/2022] Open
Abstract
Introduction Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. In order to provide the specimens that will facilitate such an understanding, The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center (KTB) was established. The KTB is, to our knowledge, the only biorepository in the world prospectively established to collect normal, healthy breast tissue from volunteer donors. As a first initiative toward a molecular understanding of the biology and developmental genetics of the normal mammary gland, the effect of the menstrual cycle and hormonal contraceptives on DNA expression in the normal breast epithelium was examined. Methods Using normal breast tissue from 20 premenopausal donors to KTB, the changes in the mRNA of the normal breast epithelium as a function of phase of the menstrual cycle and hormonal contraception were assayed using next-generation whole transcriptome sequencing (RNA-Seq). Results In total, 255 genes representing 1.4% of all genes were deemed to have statistically significant differential expression between the two phases of the menstrual cycle. The overwhelming majority (221; 87%) of the genes have higher expression during the luteal phase. These data provide important insights into the processes occurring during each phase of the menstrual cycle. There was only a single gene significantly differentially expressed when comparing the epithelium of women using hormonal contraception to those in the luteal phase. Conclusions We have taken advantage of a unique research resource, the KTB, to complete the first-ever next-generation transcriptome sequencing of the epithelial compartment of 20 normal human breast specimens. This work has produced a comprehensive catalog of the differences in the expression of protein-coding genes as a function of the phase of the menstrual cycle. These data constitute the beginning of a reference data set of the normal mammary gland, which can be consulted for comparison with data developed from malignant specimens, or to mine the effects of the hormonal flux that occurs during the menstrual cycle.
Collapse
|
31
|
Song MJ, Lee SH, Choi MR, Son HJ, Lee CW, Yoon JH, Park YG, Hur SY, Ryu KS, Lee JM. Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer. EUR J GYNAECOL ONCOL 2013; 34:148-151. [PMID: 23781586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
PURPOSE The aim of this study was to establish the guidelines for detecting early recurrences of advanced epithelial ovarian cancer by use of the CA-125 level. MATERIALS AND METHODS Eighty-five of the patients who met the inclusion criteria were enrolled in this study. The authors examined 25 incremental changes of CA125 from one to 25 IU/ml, and compared the CA-125 value with other prognostic factors. Increases in the CA-125 level from the nadir level were expressed as CA-125- increments. RESULTS Among the 25 increments, a CA-125-8 (eight IU/ml) was selected as the predictor that was the most efficient and time-effective. CA-125-8 had a sensitivity of 91.5%, a specificity of 84.6%, a positive predictive value of 93.1%, a negative predictive value of 81.5%, an efficiency of 89.4%. and a median lead-time of 68.5 days (p <0.0001). CONCLUSION The authors suggest the incremented CA-125-8 as a predictor of recurrent advanced ovarian cancer.
Collapse
Affiliation(s)
- M J Song
- Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Blaes AH, Chia V, Solid C, Page J, Barron RL, Choi MR, Arneson TJ. Abstract P1-15-01: Patterns of granulocyte colony stimulating factor (G-CSF) use in elderly breast cancer (BC) patients receiving myelosuppressive chemotherapy. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Febrile neutropenia (FN) is a common and potentially serious complication of myelosuppressive chemotherapy treatment in cancer patients. Oncology guidelines recommend primary G-CSF prophylaxis (PPG) in patients with a high risk of developing FN, which is risk >20% based on myelotoxicity of the regimen itself or from a combination of the therapy, older age, comorbidities and disease characteristics (Lyman Cancer 2011). Current patterns of G-CSF use and FN occurrence among elderly patients receiving myelosuppressive chemotherapy for BC have not been previously reported. To determine this, we performed a retrospective analysis using a subset of the Medicare 5% database.
Methods: The Medicare 5% claims data set (includes a representative 5% systematic sample of Medicare beneficiaries) was used to identify BC patients age 65+ initiating chemotherapy between 7/1/2003 and 6/30/2009. Chemotherapy courses were identified for each patient; only the first course was used for this analysis. Using the National Comprehensive Cancer Network guidelines on Myeloid Growth Factors (NCCN V1.2012), chemotherapy course regimens were classified as high risk (HR) or intermediate risk (IR) for FN. Duration of first cycle was from date of first chemotherapy claim to the chemotherapy claim at day 21 or later, which defined the first day of the second cycle, etc., to a maximum of 9 cycles. First administration of G-CSF [filgrastim (NEUPOGEN®) or pegfilgrastim (Neulasta®)] was classified as either PPG (within first 5 days of first cycle), secondary prophylaxis (within first 5 days of second or subsequent cycles), or reactive (day 6 or later of first or subsequent cycles). FN assessed during the chemotherapy course was defined as hospitalization with a code for neutropenia in any position.
Results: 885 courses with high FN risk and 1046 with IR FN risk were identified. The HR cohort was younger (71.4 vs 74.5 yrs) and had fewer comorbidities than the IR cohort. Selected aspects of G-CSF use patterns are summarized in the table. Among HR courses, 11.8% had ≥1 FN hospitalization and 2.1% had 2+; among IR courses 5.6% had ≥1 and 0.4% had 2+.
Conclusion: NCCN recommends PPG be used with HR regimens and older age (notably >65 yr), an important risk factor for developing severe neutropenic complications. Despite this, PPG was used for elderly breast cancer patients in only 52% of chemotherapy courses with high risk of FN and in 10% of IR courses. More than 10% of patients with a HR regimen had an FN hospitalization. Careful attention to FN risk factors, including regimen and patient age, is needed when planning treatment strategy.
HR regimens: TAC (389); dose dense AC→T (345); docetaxel+trastuzumab (61); doxorubicin+docetaxel (50); doxorubicin+paciltaxel (21); docetaxel q14(19). IR regimens: CMF classic (481); paclitaxel q21 (337); docetaxel q21 (94); paclitaxel+ trastuzumab (87); FEC (47).
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-15-01.
Collapse
Affiliation(s)
- AH Blaes
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| | - V Chia
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| | - C Solid
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| | - J Page
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| | - RL Barron
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| | - MR Choi
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| | - TJ Arneson
- University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN
| |
Collapse
|
33
|
Choi MR, Liu Q, Lee SY, Jin JH, Ryu S, Kang DH. Inactivation of Escherichia coli O157:H7, Salmonella typhimurium and Listeria monocytogenes in apple juice with gaseous ozone. Food Microbiol 2012; 32:191-5. [DOI: 10.1016/j.fm.2012.03.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2011] [Revised: 03/02/2012] [Accepted: 03/05/2012] [Indexed: 10/28/2022]
|
34
|
Choi NY, Baek SY, Yoon JH, Choi MR, Kang DH, Lee SY. Efficacy of aerosolized hydrogen peroxide-based sanitizer on the reduction of pathogenic bacteria on a stainless steel surface. Food Control 2012. [DOI: 10.1016/j.foodcont.2012.02.027] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
35
|
Choi MR, Bardhan R, Stanton-Maxey KJ, Badve S, Nakshatri H, Stantz KM, Cao N, Halas NJ, Clare SE. Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol 2012. [PMID: 23205151 PMCID: PMC3505533 DOI: 10.1007/s12645-012-0029-9] [Citation(s) in RCA: 113] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
As systemic cancer therapies improve and are able to control metastatic disease outside the central nervous system, the brain is increasingly the first site of relapse. The blood-brain barrier (BBB) represents a major challenge to the delivery of therapeutics to the brain. Macrophages originating from circulating monocytes are able to infiltrate brain metastases while the BBB is intact. Here, we show that this ability can be exploited to deliver both diagnostic and therapeutic nanoparticles specifically to experimental brain metastases of breast cancer.
Collapse
Affiliation(s)
- Mi-Ran Choi
- Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202 USA
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Sauder CAM, Koziel JE, Choi M, Fox MJ, Badve S, Blosser RJ, Mathieson T, Rufenbarger CA, Henry JE, Storniolo AMV, Herbert BS, Clare SE. Abstract 3322: Phenotypic plasticity in the normal breast. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-3322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Metaplasia is observed in almost all epithelial cancers. The origins of metaplasia are obscure although chronic inflammation is thought to be one etiology. We present data that suggests that an origin of metaplasia is the normal resident stem cell population. Methods: Starting from 10 gauge tissue cores of normal breast donated to the Komen Tissue Bank, 28 normal mammary epithelial (HME) and 33 normal stromal (HMS) cell lines were established using an organoid isolation method after digestion with enzymes for 24 hours. The HME cell lines were characterized by immunohistochemistry (IHC). Ploidy was assayed. Cellular morphology was observed both on two-dimensional and in three-dimensional culture systems. The HME cells were subjected to FACS analysis using multiple antibodies. Results: 96.9% of early passage cells are diploid. The HME cells express vimentin, CK 5/6, p63, CD 10, CK 18, and HER-1 when grown on two dimensional plastic surfaces. Cells placed in the center of a sandwich of Matrigel uniformly make spheres 37mm-325mm in diameter. Hematoxylin and eosin staining of the formalin-fixed and paraffin-embedded sections of these spheres reveal keratinized squamous differentiation. When the cells are grown on Laminin, Collagen Type IV, or Fibronectin surfaces multiple cell types are observed including osteoclasts, distinguished by the presence of Tartrate Resistant Acid Phospatase; and chondrocytes, confirmed by staining with Alcian Blue. Other cells with a spindle-shape and cytoplasmic vacuoles turn a dark reddish-brown color when stained with Oil Red O, characteristics of adipocytes. In other areas of the culture, the cells form a syncitium and they express the protein MyoD, a marker of immature muscle. Finally, there are numerous cells with long, dendritic processes. These cells express Nestin, glial fibrillary acidic protein (GFAP), and beta-III tubulin. Using FACS, the HME cells were found to be CD49f positive and EpCAM negative. Multiple nucleoli were confirmed using anti-Nucleostemin IHC. Conclusions: Phenotypic plasticity is common to all the HME cell lines characterized to date. Differentiation into cells of mesodermal and ectodermal origin, CD49+/EpCAM- by FACS, and the presence of multiple nucleoli suggest that the isolated cells are a multipotent/stem cell residing in the normal adult breast. These cells, through a series of yet to be elucidated events, may be the cells of origin of both benign and malignant metaplasia observed in breast lesions.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3322. doi:1538-7445.AM2012-3322
Collapse
Affiliation(s)
| | | | - MiRan Choi
- 1Indiana University School of Medicine, Indianapolis, IN
| | - Melanie J. Fox
- 1Indiana University School of Medicine, Indianapolis, IN
| | - Sunil Badve
- 1Indiana University School of Medicine, Indianapolis, IN
| | | | - Theresa Mathieson
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN
| | | | - Jill E. Henry
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN
| | | | | | - Susan E. Clare
- 1Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
37
|
Choi MR, Lee SY, Park KH, Chung MS, Ryu S, Kang DH. Effect of aerosolized malic acid against Listeria monocytogenes, Salmonella Typhimurium, and Escherichia coli O157:H7 on spinach and lettuce. Food Control 2012. [DOI: 10.1016/j.foodcont.2011.09.022] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
38
|
Bordoni RE, Haislip ST, Gilmore JW, Sharpe J, Abella E, Choi MR. P5-20-07: Estimation of Febrile Neutropenia in Women Receiving Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Early Stage Breast Cancer: A Retrospective Analysis. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-20-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: US Oncology Trial 9735 (Jones S, et al. JCO. 2006;24:5381–5387) established the docetaxel plus cyclophosphamide (TC) regimen as an effective adjuvant therapy for early stage breast cancer (ESBC). This trial did not specifically evaluate the incidence of febrile neutropenia (FN) as a study endpoint, but rates of 4%-8% were reported. Prophylactic granulocyte colony-stimulating factor (G-CSF) support was not allowed; reactive G-CSF support overall was not reported. Subsequent reports in the community setting have indicated FN rates of 25%-50% without G-CSF support and 0%-6.3% with G-CSF support (Table 1). To better determine the incidence of FN among ESBC patients treated with TC, we performed a retrospective clinical data review from the electronic medical record (EMR) database of Georgia Cancer Specialists, a large community oncology practice.
Methods: EMR data were captured between January 2006 and March 2010. Eligibility included women ≥ 18 years old with ESBC (stage I-IIIA) who completed ≥ 1 cycle of TC. The study time period was from the first dose of chemotherapy (CTX) to 6 weeks after the last dose of CTX, death, or loss to follow-up. The primary endpoint was the incidence of FN. Other endpoints included the incidence of severe (grade 3/4) neutropenia, neutropenia-related hospitalizations, G-CSF use, relative dose intensity (RDI), and dose delays and reductions. Results: Data from 662 patients were included in the analysis. Median age was 55 (range: 25–81) years. 40% of patients were white. The median number of CTX cycles received was 4 (range: 1–6). Most patients (91%) received G-CSF support; 73% as primary prophylaxis. See Table 2 for additional results.
Conclusions: This is the largest retrospective, community-based study to evaluate the incidence of FN in ESBC patients treated with TC. The observed FN rate of 5% (with 91% of patients receiving G-CSF) is consistent with other published reports using TC (Table 1). Our results suggest that TC is a taxane regimen with clinically significant myelosuppression (similar to other commonly used regimens in ESBC, such as TAC [NCCN Guidelines v2.2011]) and that the use of G-CSF support should always be considered.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-20-07.
Collapse
Affiliation(s)
- RE Bordoni
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - ST Haislip
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - JW Gilmore
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - J Sharpe
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - E Abella
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - MR Choi
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
39
|
Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, Chun HS, Lee KW, Yoon Park JH. Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res 2011; 13:R78. [PMID: 21834963 PMCID: PMC3236342 DOI: 10.1186/bcr2927] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2011] [Revised: 06/19/2011] [Accepted: 08/11/2011] [Indexed: 12/22/2022] Open
Abstract
Introduction High-fat diets (HFDs) are known to cause obesity and are associated with breast cancer progression and metastasis. Because obesity is associated with breast cancer progression, it is important to determine whether dietary fat per se stimulates breast cancer progression in the absence of obesity. This study investigated whether an HFD increases breast cancer growth and metastasis, as well as mortality, in obesity-resistant BALB/c mice. Methods The 4-week-old, female BALB/c mice were fed HFD (60% kcal fat) or control diet (CD, 10% kcal fat) for 16 weeks. Subsequently, 4T1 mammary carcinoma cells were injected into the inguinal mammary fat pads of mice fed continuously on their respective diets. Cell-cycle progression, angiogenesis, and immune cells in tumor tissues, proteases and adhesion molecules in the lungs, and serum cytokine levels were analyzed with immunohistochemistry, Western blotting, and enzyme-linked immunosorbent assay (ELISA). In vitro studies were also conducted to evaluate the effects of cytokines on 4T1 cell viability, migration, and adhesion. Results Spleen and gonadal fat-pad weights, tumor weight, the number and volume of tumor nodules in the lung and liver, and tumor-associated mortality were increased in the HFD group, with only slight increases in energy intake and body weight. HF feeding increased macrophage infiltration into adipose tissues, the number of lipid vacuoles and the expression of cyclin-dependent kinase (CDK)2, cyclin D1, cyclin A, Ki67, CD31, CD45, and CD68 in the tumor tissues, and elevated serum levels of complement fragment 5a (C5a), interleukin (IL)-16, macrophage colony-stimulating factor (M-CSF), soluble intercellular adhesion molecule (sICAM)-1, tissue inhibitors of metalloproteinase (TIMP)-1, leptin, and triggering receptor expressed on myeloid cells (TREM)-1. Protein levels of the urokinase-type plasminogen activator, ICAM-1, and vascular cell adhesion molecule-1 were increased, but plasminogen activator inhibitor-1 levels were decreased in the lungs of the HFD group. In vitro assays using 4T1 cells showed that sICAM-1 increased viability; TREM-1, TIMP-1, M-CSF, and sICAM-1 increased migration; and C5a, sICAM-1, IL-16, M-CSF, TIMP-1, and TREM-1 increased adhesion. Conclusions Dietary fat increases mammary tumor growth and metastasis, thereby increasing mortality in obesity-resistant mice.
Collapse
Affiliation(s)
- Eun Ji Kim
- Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University, 39 Hallymdaehak-gil, Chuncheon, 200-702, Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Park SH, Choi MR, Park JW, Park KH, Chung MS, Ryu S, Kang DH. Use of organic acids to inactivate Escherichia coli O157:H7, Salmonella Typhimurium, and Listeria monocytogenes on organic fresh apples and lettuce. J Food Sci 2011; 76:M293-8. [PMID: 21623781 DOI: 10.1111/j.1750-3841.2011.02205.x] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
UNLABELLED This study was undertaken to investigate the antimicrobial effect of organic acids against Escherichia coli O157:H7, Salmonella Typhimurium, and Listeria monocytogenes on whole red organic apples and lettuce. Several studies have been conducted to evaluate organic acids as sanitizers. However, no studies have compared antimicrobial effects of various organic acids on organic fresh produce, including evaluation of color changes of produce. Apples and lettuce were inoculated with a cocktail of 3 strains each of 3 foodborne pathogens provided above and treated with 1% and 2% organic acids (propionic, acetic, lactic, malic, and citric acid) for 0, 0.5, 1, 5, and 10 min. With increasing treatment time and acid concentration, organic acid treatments showed significant reduction compared to the control treatment (distilled water), and differences in antimicrobial effects between organic acids were observed. After 10 min of treatment with 1% and 2% organic acids in apples, propionic (0.92 to 2.75 log reduction), acetic (0.52 to 2.78 log reduction), lactic (1.69 to >3.42 log reduction), malic (1.48 to >3.42 log reduction), and citric acid (1.52 to >3.42 log reduction) exhibited significant (P < 0.05) antibacterial effects against 3 foodborne pathogens compared to the control treatment. In lettuce, propionic (0.93 to 1.52 log reduction), acetic (1.13 to 1.74 log reduction), lactic (1.87 to 2.54 log reduction), malic (2.32 to 2.98 log reduction), and citric acid (1.85 to 2.86 log reduction) showed significant (P < 0.05) effects compared to the control treatment. Changes in sample color subjected to organic acids treatment were not significant during storage. PRACTICAL APPLICATION It is suggested that organic acids have a potential as sanitizers for organic fresh produce. These data may help the organic produce industry provide safe fresh produce for consumers.
Collapse
Affiliation(s)
- Sang-Hyun Park
- Dept. of Food and Animal Biotechnology, Center for Agricultural Biomaterials, and Research Inst. for Agriculture and Life Sciences, Seoul Natl. Univ., Seoul 151-921, Republic of Korea
| | | | | | | | | | | | | |
Collapse
|
41
|
Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, Park JHY. Abstract 5562: High-fat diet feeding increases tumor growth and metastasis of mammary carcinoma cells in the 4T1 orthotopic BALB/c mouse model. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-5562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We previously observed that chronic consumption of a high fat-diet (HFD) increased the breast cancer-related mortality in the 4T1 orthotopic mouse breast cancer model. In the present study, we determined whether feeding mice with a HFD for a prolonged period increases solid tumor growth and metastasis of breast cancer cells using the 4T1 orthotopic model. 4-week old, female BALB/c mice were fed a purified diet containing 60 kcal% fat (HFD) or 10 kcal% fat (control diet) for a period of 16 weeks. After 16 weeks, 4T1 mammary carcinoma cells (5 × 104 cells) were injected into the inguinal mammary fat pad of syngeneic female BALB/c mice and the mice were continuously fed the same diets. Solid tumor growth was increased in the HFD group as compared to the control diet group. Additionally, chronic consumption of the HFD markedly increased the number and volume of tumor nodules in the lung and liver. The expression of cyclin-dependent kinase (CDK)2, CDK4, cyclin D1, cyclin A, Ki67, vascular endothelial growth factor, CD31 (an angiogenesis marker), and CD45 (a monocyte/macrophage marker) was markedly increased in the tumor tissues in the HFD group as compared to control diet group. The protein levels of urokinase-type plasminogen activator (uPA), intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule-1 were significantly increased but those of plasminogen activator inhibitor-1 were decreased in the lung tissues of the HFD group as compared to control diet group. The serum levels of complement fragment 5a (C5a), interleukin (IL)-6, macrophage colony stimulating factor (M-CSF), soluble intercellular adhesion molecule (sICAM)-1, tissue inhibitors of metalloproteinase (TIMP)-1, and triggering receptor expressed on myeloid cells (TREM)-1 were up-regulated in the HFD group as compared to control diet group. We conducted in vitro assays to determine effect of these cytokines, which had been increased in the sera of mice fed on the HFD, on the cell proliferation, adhesion, and migration of 4T1 cells. sICAM-1 increased the viability of 4T1 cells. TREM-1, M-CSF, and sICAM-1 significantly increased the migration of 4T1 cells. Additionally, the capacity of 4T1 cells to adhere to strips coated with human collagen type I was increased by C5a, sICAM-1, IL-16, M-CSF, TIMP-1, and TREM-1. These results indicate that, in addition to adhesion molecules, metalloproteases and pro-angiogenic factors, the cytokines C5a, sICAM-1, IL-16, M-CSF, TIMP-1, and TREM-1 play important roles in the metastasis of mammary cancer cells in mice fed on a HFD for a prolonged period.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5562. doi:10.1158/1538-7445.AM2011-5562
Collapse
Affiliation(s)
- Eun Ji Kim
- 1Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym Univ., Chuncheon, Korea, Republic of
| | - Mi-Ran Choi
- 1Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym Univ., Chuncheon, Korea, Republic of
| | - Heesook Park
- 2Department of Food Science and Nutrition, Hallym Univ., Chuncheon, Korea, Republic of
| | - Minhee Kim
- 2Department of Food Science and Nutrition, Hallym Univ., Chuncheon, Korea, Republic of
| | - Ji Eun Hong
- 1Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym Univ., Chuncheon, Korea, Republic of
| | - Jae-Yong Lee
- 3Department of Biochemistry, College of Medicine, Hallym Univ., Chuncheon, Korea, Republic of
| | - Jung Han Yoon Park
- 2Department of Food Science and Nutrition, Hallym Univ., Chuncheon, Korea, Republic of
| |
Collapse
|
42
|
Vandenberg T, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Chan A. Abstract P3-15-02: Underreporting of Myelotoxicity with Emerging Breast Cancer Regimens. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-15-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although many emerging regimens that incorporate targeted agents may produce increased myelosuppressive side-effects, clinical data guiding colony-stimulating factor (CSF) use with these regimens are not readily available. This review assessed the reporting diligence around febrile neutropenia and the related use of CSF and antibiotics in published clinical trials evaluating emerging regimens for breast cancer treatment.
Methods: We searched Medline, EMBASE, and Cochrane databases to identify randomized, controlled phase 3 breast cancer studies published between Jan 2005 and June 2009. After excluding trials of vaccines, hormonal therapy alone, and stem cell transplantation/mobilization, corresponding publications were retrieved and data extracted on the incidence of neutropenia and its complications and CSF/antibiotic use. We then calculated the percentage of these publications that reported each outcome.
Results: Of 463 trials identified from the search, only 73 met the inclusion criteria. Overall, 70% and 55% of trials reported the incidence of grade 3/4 neutropenia and febrile neutropenia, respectively (Table). Neutropenia-related hospitalizations were reported in 3% of trials. Prophylactic use of CSF and antibiotics was defined in the methods section of 59% and 23% of trials, respectively; and only reported in the results section of 22% and 5% of trials, respectively.
Conclusion: Clinically significant neutropenia and neutropenia-related events (including febrile neutropenia) were generally described in the studies evaluated; however, the reported use of CSF and/or antibiotics was infrequent and inconsistent in the published literature of emerging regimens. A standardized approach to reporting neutropenic outcomes as well as the use of supportive care measures can assist cliniciansto prospectively manage the relevant toxicities associated with these emerging regimens and thereby facilitate their safe and effective use in clinical practice.
Table: Reporting of myelotoxicity data in published phase 3 trials
CSF = colony-stimulating factor
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-15-02.
Collapse
Affiliation(s)
- T Vandenberg
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| | - S Verma
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| | - S Loibl
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| | - J Crawford
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| | - MR Choi
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| | - L Dreiling
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| | - A. Chan
- University of Western Ontario, London, Canada; Ottawa Hospital Cancer Center, ON, Canada; German Breast Group, Neu-Isenburg, Germany; Duke University Medical Center, Durham, NC; Amgen Inc, Thousand Oaks, CA; Mount Medical Center, Perth, Australia
| |
Collapse
|
43
|
Huang S, Day TW, Choi MR, Safa AR. Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity. Mol Cell Biochem 2009; 331:81-8. [PMID: 19415457 PMCID: PMC4450256 DOI: 10.1007/s11010-009-0147-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2008] [Accepted: 04/23/2009] [Indexed: 01/15/2023]
Abstract
Taxol triggers apoptosis in a variety of cancer cells, but it also upregulates cytoprotective proteins and/or pathways that compromise its therapeutic efficacy. In this report, we found that Taxol treatment resulted in caspase-8-dependent apoptosis in SKOV3 human ovarian cancer cells. Moreover, Taxol-induced apoptosis was associated with caspase-3 activation. Interestingly, Taxol treatment upregulated alpha-2,3-sialyltransferase (ST3Gal III) expression and forced expression of ST3Gal III attenuated Taxol-induced apoptosis. Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.
Collapse
Affiliation(s)
- Su Huang
- Department of Pharmacology and Toxicology, Indiana University Simon Cancer Center, Indiana University School of Medicine, 1044 West Walnut St. R4-119, Indianapolis, IN 46202, USA
| | | | | | | |
Collapse
|
44
|
Choi MR, Najafi F, Safa AR, Drexler HCA. Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI. Biochem Pharmacol 2008; 75:2276-88. [PMID: 18468579 DOI: 10.1016/j.bcp.2008.03.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Revised: 03/19/2008] [Accepted: 03/20/2008] [Indexed: 02/07/2023]
Abstract
Proteasome inhibitors display potent anti-neoplastic and anti-angiogenic properties both in vitro and in vivo. The mechanisms, however, by which proteasome inhibitors kill tumor cells are still fairly elusive as is the molecular basis of resistance to treatment. To address these questions, we employed a high-throughput Western blotting procedure to analyze changes in a subproteome of approximately 800 proteins in the promyelocytic leukemia cell line HL-60 upon treatment with the proteasome inhibitor PSI (Z-Ile-Glu(OtBu)-Ala-Leu-aldehyde) and correlated the changes of selected target proteins with the changes in two multidrug-resistant HL-60 variants. In total, 105 proteins were upregulated more than 1.5-fold after PSI treatment, while 79 proteins were downregulated. Activation of caspases-3 and -8, modulation of members of the Bcl-2 family as well as stimulation of stress signaling pathways was prominent during HL-60 apoptosis. We also identified changes in the abundance of proteins previously not known to be affected by proteasome inhibitors. In contrast, two multidrug-resistant HL-60 cell lines, overexpressing either MRP1 or P-glycoprotein were largely resistant to PSI-induced apoptosis and could not be resensitized by the pharmacological inhibitors of the drug efflux pumps MK571 or PSC833. Drug resistance was also independent of the upregulation of Bad. Overexpression of multidrug resistance proteins, P-glycoprotein and MRP-1 is thus not sufficient to explain resistance of HL-60 cells to treatment with proteasome inhibitor PSI, which remains more closely related to a low level of Bax expression and to the inability to activate JNK. Alternative routes to the acquisition of resistance to PSI have therefore to be considered.
Collapse
Affiliation(s)
- Mi-Ran Choi
- Max Planck Institute for Molecular Biomedicine, Department for Vascular Cell Biology, Roentgenstr. 20, 48149 Muenster, Germany.
| | | | | | | |
Collapse
|
45
|
Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, Badve S, Sturgis J, Robinson JP, Bashir R, Halas NJ, Clare SE. A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007; 7:3759-65. [PMID: 17979310 DOI: 10.1021/nl072209h] [Citation(s) in RCA: 323] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Destruction of hypoxic regions within tumors, virtually inaccessible to cancer therapies, may well prevent malignant progression. The tumor's recruitment of monocytes into these regions may be exploited for nanoparticle-based delivery. Monocytes containing therapeutic nanoparticles could serve as "Trojan Horses" for nanoparticle transport into these tumor regions. Here we report the demonstration of several key steps toward this therapeutic strategy: phagocytosis of Au nanoshells, and photoinduced cell death of monocytes/macrophages as isolates and within tumor spheroids.
Collapse
Affiliation(s)
- Mi-Ran Choi
- Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
RhoGDI2, a cytosolic regulator of Rho GTPase, is cleaved during apoptosis in a caspase-3 dependent fashion. By using 2D-gel electrophoresis, mass spectrometry and Western blotting we investigate in this paper the functional consequences of RhoGDI2 processing. We can show that loss of the N-terminal 19 amino acids results in a shift of the isoelectric point of the truncated RhoGDI2 (NDelta19) to a more basic value due to the removal of 9 acidic amino acids from the N-terminus, which may be responsible for enhanced retention of the N-terminally truncated protein within the nuclear compartment. Fusion of the p53 nuclear export signaling sequence MFRELNEALELK to NDelta19 (NDelta19NES) abolished its apoptosis promoting properties, while overexpression of NDelta19 significantly increased the susceptibility to apoptosis induction by the proteasome inhibitor PSI and by staurosporine. These results suggest that cleavage of RhoGDI2 by caspase-3 is not a functionally irrelevant bystander effect of caspase activation during apoptosis, but rather expedites progression of the apoptotic process.
Collapse
MESH Headings
- Amino Acid Sequence
- Apoptosis/genetics
- Apoptosis/physiology
- Caspases/physiology
- Electrophoresis, Gel, Two-Dimensional
- Guanine Nucleotide Dissociation Inhibitors/genetics
- Guanine Nucleotide Dissociation Inhibitors/metabolism
- HL-60 Cells
- Humans
- K562 Cells
- Leukemia, Erythroblastic, Acute/metabolism
- Leukemia, Erythroblastic, Acute/pathology
- Leukemia, Promyelocytic, Acute/metabolism
- Leukemia, Promyelocytic, Acute/pathology
- Molecular Sequence Data
- RNA Processing, Post-Transcriptional
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- Tumor Cells, Cultured
- Tumor Suppressor Proteins/genetics
- Tumor Suppressor Proteins/metabolism
- U937 Cells
- rho Guanine Nucleotide Dissociation Inhibitor beta
- rho-Specific Guanine Nucleotide Dissociation Inhibitors
Collapse
Affiliation(s)
- Mi-Ran Choi
- Max-Planck-Institute for Heart and Lung Research, Parkstr.1, Bad Nauheim 61231, Germany
| | | | | |
Collapse
|
47
|
Shin H, Chang HJ, Boyd RW, Choi MR, Jo W. Large nonlinear optical response of polycrystalline Bi3.25La0.75Ti3O12 ferroelectric thin films on quartz substrates. Opt Lett 2007; 32:2453-5. [PMID: 17700816 DOI: 10.1364/ol.32.002453] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
We measure the nonlinear susceptibility of Bi(3.25)La(0.75)Ti(3)O(12) (BLT) thin films grown on quartz substrates using the Z-scan technique with picosecond laser pulses at a wavelength of 532 nm. The third-order nonlinear refractive index coefficient gamma and absorption coefficient beta of the BLT thin film are 3.1 x 10(-10) cm(2)/W and 3 x 10(-5) cm/W, respectively, which are much larger than those of most ferroelectric films. The results show that the BLT thin films on quartz substrates are good candidate materials for applications in nonlinear optical devices.
Collapse
Affiliation(s)
- Heedeuk Shin
- The Institute of Optics, University of Rochester, Rochester, NY 14627, USA
| | | | | | | | | |
Collapse
|
48
|
Lee JH, Oh YJ, Kim TY, Choi MR, Jo W. Piezoelectric and electromechanical properties of relaxor ferroelectric Pb(Mg1/3Nb2/3)O3(65%)-PbTiO3(35%) thin films observed by scanning force microscopy. Ultramicroscopy 2007; 107:954-7. [PMID: 17570592 DOI: 10.1016/j.ultramic.2007.02.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Accepted: 02/09/2007] [Indexed: 10/23/2022]
Abstract
Relaxor ferroelectric PbMg(1/3)Nb(2/3)O(3)(65%)-PbTiO(3)(35%) (PMN-35PT) thin films were grown by a sol-gel method on Pt(111)/TiO(2)/SiO(2)/Si(100) substrates. Piezoresponse and poling behavior appear to have a relation with the relaxor behavior of the materials. Piezoelectric images were studied in a number of regions on the films with subsequent statistical analysis of the obtained data using the contact mode of scanning force microscopy. Hysteresis loops were observed with external field applied over a wide range of the vibration frequency. The piezoelectric coefficient, d(33), and the crystallographic electrostrictive constant, Q(33), were also determined as 100pm/V and 2.8x10(-3)C(-2)m(4), respectively.
Collapse
Affiliation(s)
- J H Lee
- Department of Physics and Division of Nanosciences, Ewha Womans University, Seoul 120-750, Republic of Korea
| | | | | | | | | |
Collapse
|
49
|
Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol 2006; 72:293-307. [PMID: 16753135 DOI: 10.1016/j.bcp.2006.04.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2006] [Revised: 04/17/2006] [Accepted: 04/19/2006] [Indexed: 11/17/2022]
Abstract
The death-inducing cytokine TRAIL is a promising agent for anticancer therapy since it preferentially kills cancer versus normal cells; however, some cancer cells are TRAIL-resistant. We initially explored whether overexpression of the MDR1 gene product P-glycoprotein (P-gp), which causes multidrug resistance (MDR) in cancer cells, also contributes to TRAIL-resistance. Surprisingly, our results revealed that P-gp-overexpression enhances TRAIL-induced apoptosis not only in neoplastic cells transfected with the MDR1 gene but also in MDR variants selected with cytotoxic anticancer agents. Mechanistic analysis of TRAIL-induced apoptosis in the MDR1-transfected MCF-7 breast cancer cell line BC-19 revealed that TRAIL-triggered significantly more apoptosis in these cells compared with parental MCF-7 cells by binding to the TRAIL receptor DR5. DR5 but not DR4 engagement by TRAIL attenuated cellular ATP levels by robustly stimulating P-gp ATPase activity, and thus triggered P-gp-dependent apoptosis by depletion of the cellular ATP pool. In addition to hyperactive P-gp-mediated ATP hydrolysis, TRAIL-induced, P-gp-potentiated apoptosis was associated with activation of caspases-6, -7, -8, and -9; Bid cleavage; and mitochondrial depolarization. P-gp interacted with the TRAIL receptors DR4, DR5, and DcR1 in plasma membranes and enhanced TRAIL binding to DR5. Interestingly, the decreased level of the decoy TRAIL receptor, DcR1, in BC-19 cells further sensitized these cells to TRAIL. Therefore, both extrinsic and intrinsic apoptosis pathways are involved in this process. These findings for the first time reveal that TRAIL treatment preferentially causes apoptosis in P-gp-overexpressing MDR cells, and suggests significant clinical implications for the use of TRAIL in treating neoplasms that have failed chemotherapy.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- Adenosine Triphosphate/metabolism
- Antibodies/pharmacology
- Antineoplastic Agents/pharmacology
- Apoptosis/drug effects
- Apoptosis Regulatory Proteins/metabolism
- Apoptosis Regulatory Proteins/pharmacology
- Caspase 8
- Caspases/metabolism
- Cell Line, Tumor
- Cytochromes c/metabolism
- Dose-Response Relationship, Drug
- Doxorubicin/pharmacology
- Drug Resistance, Multiple/genetics
- Drug Resistance, Neoplasm/genetics
- Enzyme Activation/drug effects
- Humans
- Membrane Glycoproteins/metabolism
- Membrane Glycoproteins/pharmacology
- Membrane Potentials/drug effects
- Mitochondrial Membranes/drug effects
- Mitochondrial Membranes/physiology
- Paclitaxel/pharmacology
- Protein Binding
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor/immunology
- Receptors, Tumor Necrosis Factor/metabolism
- TNF-Related Apoptosis-Inducing Ligand
- Transfection
- Tumor Necrosis Factor-alpha/metabolism
- Tumor Necrosis Factor-alpha/pharmacology
- Vinblastine/pharmacology
Collapse
Affiliation(s)
- Soo-Jung Park
- Department of Pharmacology and Toxicology, Indiana University Cancer Center, 1044 West Walnut R4-119, Indianapolis, 46202, USA
| | | | | | | | | | | |
Collapse
|
50
|
Baik SY, Jung KH, Choi MR, Yang BH, Kim SH, Lee JS, Oh DY, Choi IG, Chung H, Chai YG. Fluoxetine-induced up-regulation of 14-3-3zeta and tryptophan hydroxylase levels in RBL-2H3 cells. Neurosci Lett 2005; 374:53-7. [PMID: 15631896 DOI: 10.1016/j.neulet.2004.10.047] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2004] [Revised: 10/04/2004] [Accepted: 10/10/2004] [Indexed: 11/21/2022]
Abstract
The primary mechanisms of antidepressants are based on the monoamine depletion hypothesis. However, we do not yet know the full cascade of mechanisms responsible for the therapeutic effect of antidepressants. To identify the genes involved in the therapeutic mechanism of the selective serotonin reuptake inhibitor, fluoxetine, we used a cDNA microarray analysis with RBL-2H3 cells. We observed the transcriptional changes of several tens of genes containing the 14-3-3zeta gene in the fluoxetine-treated RBL-2H3 cells. Real-time RT-PCR and Western blotting confirmed changes in the expression of the gene and protein. The increase of 14-3-3zeta mRNA was observed at 72 h in the fluoxetine-treated RBL-2H3 cells. The increase of 14-3-3zeta protein was observed at 48 and 72 h. In this study, the expressions of the 14-3-3zeta gene and the protein were up-regulated at 72 h. In addition, the increase of TPH mRNA was observed at 12, 24 and 72 h in the fluoxetine-treated RBL-2H3 cells. We conclude that fluoxetine induces increases of 14-3-3zeta mRNA, 14-3-3zeta protein and TPH mRNA at 72 h in the RBL-2H3 cells. This suggests that the 14-3-3zeta and TPH genes may play a role in the molecular mechanism of fluoxetine. To date, no cases of 14-3-3zeta alterations by antidepressants and specifically by fluoxetine have been reported.
Collapse
Affiliation(s)
- Seung-Youn Baik
- Department of Biochemistry, Division of Molecular and Life Sciences, Hanyang University, Ansan 426-791, Republic of Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|